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Joanna K. Sax* 
ABSTRACT 
Society is facing major challenges in climate change, health care and 
overall quality of life.  Scientific advances to address these areas continue to 
grow, with overwhelming evidence that the application of highly tested forms of 
biotechnology is safe and effective.  Despite scientific consensus in these areas, 
consumers appear reluctant to support their use.  Research that helps to 
understand consumer decision-making and the public’s resistance to 
biotechnologies such as vaccines, fluoridated water programs and genetically 
engineered food, will provide great social value.  This article is forward-thinking 
in that it suggests that important research in behavioral decision-making, 
specifically affect and ambiguity, can be used to help consumers make informed 
choices about major applications of biotechnology.  This article highlights some 
of the most controversial examples: vaccinations, genetically engineered food, 
rbST treated dairy cows, fluoridated water, and embryonic stem cell research.  In 
many of these areas, consumers perceive the risks as high, but the experts 
calculate the risks as low.  Four major thematic approaches are proposed to create 
a roadmap for policymakers to consider for policy design and implementation in 
controversial areas of biotechnology.  This article articulates future directions 
for studies that implement decision-making research to allow consumers to 
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INTRODUCTION 
Despite overwhelming scientific evidence supporting the 
application of biotechnology to address major social issues, consumers 
are resisting policies that apply science to solve major challenges.  This 
article utilizes theories in behavioral decision-making research not 
only to articulate why consumers may be hesitant to accept 
biotechnology, but proposes to deeply study and analyze ways to 
assuage the public’s concerns.  Consumers are bombarded with 
conflicting information regarding each area of technology and, not 
surprisingly, struggle to separate the wheat from the chaff.  A 
tremendous amount of resources is dedicated to evaluating risk, yet 
not enough attention is given to how consumers perceive risk.  This 
lack of attention creates a major problem for policy implementation.  
In other words, expert analysis of risk is not translating into consumer 
perceptions of risk.  This article seeks to present a roadmap of studies 
that implement decision-making research to translate the empirical 
evidence of risk analysis in ways that allow consumers to appropriately 
assign risk to various areas of biotechnology, such as vaccines. 
Every day most of us experience the benefits of science and, in 
particular, biotechnology.  Even the small parts of our days are 
influenced by biotechnology, such as pouring milk in our morning 
coffee, providing food for ourselves and our families, drinking water, 
and avoiding otherwise contractible diseases.  These daily routines are 
enabled and facilitated by various scientific advances: rbST treated 
dairy cows, conventional and genetically engineered food, fluoridated 
water, and vaccines, respectively.  Policies implementing these 
technologies, based on scientific evidence, provide great social value, 
even though consumers may not fully understand the underlying 
technology.  Some consumers may not even think about the 
underlying technology, unless and until they are provided with 
information—or mis-information—that causes great concern. 
Public health officials tout many of the advances in science as 
some of our greatest achievements, particularly fluoridated water and 
vaccination programs.1  In general, public health officials promote 
group rights and look at the population as a whole when analyzing 
benefits.  For example, if vaccination programs all but eliminate an 
otherwise serious disease, such as smallpox, with little to no otherwise 
 
 1  See, e.g., Community Water Fluoridation, CTR. FOR DISEASE CONTROL, 
http://www.cdc.gov/fluoridation/index.htm (last updated July 29, 2015); Why Are 
Childhood Vaccines So Important?, CTR. FOR DISEASE CONTROL, 
http://www.cdc.gov/vaccines/vac-gen/howvpd.htm#why (last updated May 19, 2014) 
[hereinafter CDC, Why Are Childhood Vaccines So Important?].  
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measurable harm, then the benefit greatly outweighs the risk.2  
Increasingly, however, calls for the removal of rbST from dairy cows, 
elimination of fluoridated water, labeling of food based on safety 
concerns, and personal exemptions from vaccination programs are 
heard from consumers.  It is important to understand not only why 
these consumers raise concerns (e.g., whether it is from marketing or 
political campaigns) but also, how to allay their concerns—especially 
if the concerns are based on inchoate fears.  This tension between 
widespread policy implementation and opposition by individuals 
creates issues for innovation and policy implementation.  This article 
attempts to articulate and understand consumer preference as it 
relates to the application of biotechnology.  In the United States, the 
federal government invests the lion’s share of resources in assessing 
risk, but there remains a pressing need for investment in 
understanding why consumers perceive risk differently than expert 
analysis.3 
Given the strong scientific evidence supporting many of the 
widespread programs, such as vaccines and fluoridated water, we, as a 
society, need to understand why some consumers are resisting these 
programs, especially the mandatory programs.4  Efforts are underway 
to remove fluoride from public water supplies, for example.5  The 
discord with the application of biotechnology is not limited to 
widespread public health programs; it is also strong in other areas such 
as genetically engineered food, rbST treated cows, funding for 
embryonic stem cell research, and others.  This article tackles these 
issues and articulates a theme that is seen throughout all of these 
controversial areas, which is that consumers are inappropriately 
assigning risk to the application of these scientific advances.  To do 
this, this article builds on decision-making research to suggest reasons 
why consumers are averse to the implementation of policies that apply 
biotechnology. 
In risk perception research, scholars study consumer preferences 
 
 2  See, e.g., Why Immunize?, CTR. FOR DISEASE CONTROL, 
http://www.cdc.gov/vaccines/vac-gen/why.htm (last updated Sept. 23, 2014) 
[hereinafter CDC, Why Immunize?].  
 3  Cf. WERNER TROESKEN, THE POX OF LIBERTY 1, 14–38 (2015). 
 4  See, e.g., George Johnson, The Widening World of Hand-Picked Truths, N.Y. TIMES, 
Aug. 24, 2015. 
 5  See Stephanie Innes, Cavities Again? Blame the Tucson Water System. . ., ARIZ. DAILY 
STAR, Nov. 2, 2014, http://tucson.com/news/science/health-med-fit/cavities-again-
blame-the-tucson-water-system/article_33d26ed3-2fb0-5385-b14c-e97630237f4e.html 
(“An increasingly vocal opposition to fluoridated water has emerged in recent years, 
fueled by a distrust in government.”). 
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for various technologies.6  A profound example of a disconnect 
between scientists and consumers is the perception of risk of nuclear 
power.7  While experts generally find nuclear power to be a safe and 
clean source of energy, consumers perceive it as a highly risky activity.8  
Understanding these perceptions of risk is a robust area of study and 
is important for both appreciating and assuaging public concerns and 
fears.  Three Mile Island, the notorious nuclear power plant leak, is oft 
cited for qualifying the public push-back to nuclear power plants.9  
Empirical data, however, demonstrates that rates of cancer and other 
related diseases are no greater for the population surrounding Three 
Mile Island compared to the population in general.10  In other words, 
there is no measurable health harm attributable to the leak.  Despite 
this, research shows that consumers find nuclear power plants to be 
risky, with cost playing an additional role.11  As such, the public 
perceptions and concerns have all but eliminated the nuclear power 
industry.12  This has occurred despite expert opinion on safety and 
utility to the contrary.13  Perhaps other energy industries have a vested 
interest in feeding consumer concerns; or perhaps the debate about 
 
 6  Paul Slovic, Perception of Risk, 236 SCI. 280, 281 (1987) [hereinafter Slovic, 
Perception of Risk].  The author thanks a colleague for introducing Paul Slovic’s work to 
allow the author to understand and incorporate components of risk perception 
research into the author’s research (personal communication). 
 7  Id. 
 8  Id. (citing published articles therein). 
 9  See Backgrounder on the Three Mile Island Accident, U.S. NUCLEAR REG. COMMISSION, 
http://www.nrc.gov/reading-rm/doc-collections/fact-sheets/3mile-isle.html (last 
updated Dec. 12, 2014) (“A combination of personnel error, design deficiencies, and 
component failures caused the Three Mile Island accident, which permanently 
changed both the nuclear industry and the NRC.  Public fear and distrust increased, 
NRC’s regulations and oversight became broader and more robust, and management 
of the plants was scrutinized more carefully.”). 
 10  Id. (“[C]omprehensive investigations and assessments by several well respected 
organizations, such as Columbia University and the University of Pittsburgh, have 
concluded that in spite of serious damage to the reactor, the actual release had 
negligible effects on the physical health of individuals or the environment.”). 
 11  See, e.g., Bryan Walsh, Nuclear Energy is Largely Safe. But Can it be Cheap?, TIME 
(July 8, 2013), http://science.time.com/2013/07/08/nuclear-energy-is-largely-safe-
but-can-it-be-cheap/ (“And while fears of accidents and radioactivity clearly play a role 
in that decline, cost is an even bigger factor.”). 
 12  See id. (“[I]n the U.S. and much of the rest of the developed world, nuclear 
energy is in retreat, with new reactors on hold and aging ones being retired.  And while 
fears of accidents and radioactivity clearly play a role in that decline, cost is an even 
bigger factor.”).  
 13  See id. (“Accidents are rare, and those that have occurred—including the partial 
meltdown in Fukushima, Japan, in 2011—have resulted in few deaths.  On a megawatt-
per-megawatt basis, nuclear kills fewer people than almost any other source of 
electricity . . . .”).  
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which source of energy is better—such as wind, solar, natural gas, or 
nuclear—makes it challenging for consumer decision-making, given 
the limitations of a typical consumer’s knowledge about highly 
scientific information.  In other words, the advantages and 
disadvantages of each type of energy source require complicated 
discussions that may require expertise. 
A similar disconnect about the assignment of risk is occurring in 
the application of biotechnology.  Sectors of the public are wary of 
various programs and technologies despite scientific consensus to the 
contrary.  Understanding these perceptions is critical to creating 
policies that are acceptable to consumers––so that vaccinations 
programs, for example, do not face the same type consumer objections 
as nuclear power plants.  Research is needed to get a foothold on 
understanding not only why consumer perceptions are different from 
expert analysis but to also evaluate approaches that allow consumers 
to appropriately assign risk. 
This article addresses the important question of how to create 
policies that not only reap the benefits of biotechnology to solve major 
challenges, but also have the ability to be accepted and trusted by 
consumers.  To begin this evaluation, Part I describes theories that 
elucidate how consumers appropriately or inappropriately assign risk 
as part of decision-making.  This article draws on scholarship that 
advances two general theories––affect and ambiguity.14  After this 
general explanation of decision-making theories, this article turns to a 
description of some major areas of biotechnology that are hotly 
debated.  Part II thus describes the contours of debates surrounding 
vaccinations, genetically engineered food, rbST treated dairy cows, 
fluoridated water programs and embryonic stem cell research––this 
analysis includes both the scientific consensus and the various 
consumer perceptions.  Finally, Part III combines the decision-making 
theories with the scientific areas to articulate four themes to be 
considered for creating policies that assuage public concerns and 
perceptions.  These themes provide an overarching approach to 
understanding and addressing consumer concerns regarding the 
implementation of controversial areas of technology.  The four themes 
are: (1) Separate the wheat from the chaff: allow consumers to make 
informed choices; (2) Scientific uncertainty is different than risk; (3) 
Explore different methods of communication that consider the role of 
affect and ambiguity; and (4) Address the difference between values, 
 
 14  Paul Slovic et al., The Affect Heuristic, 177 EUR. J. OF OPERATIONAL RES. 1333, 1333 
(2007) [hereinafter Slovic, The Affect Heuristic]; Daniel Ellsberg, Risk, Ambiguity, and the 
Savage Axioms, 75 Q. J. OF ECON. 643, 643–69 (1961). 
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affect and ambiguity in decision-making.  Within each theme, however, 
is a detailed discussion of the various similarities and differences 
between and among each example (vaccines, genetically engineered 
food, rbST, fluoridated water and embryonic stem cell research).  Each 
example requires specific attention and proposals for conducting 
studies geared towards the individual issues raised, which are included 
herein.  This article builds on many studies in the sciences, including 
decision-making research and the basic sciences, to promote future 
directions that acknowledge the problems we face and seeks to allow 
consumers to make informed decisions. 
I. DECISION-MAKING THEORIES 
How consumers assign risk to new technologies is a key 
component to understanding decision-making.  Two major theories––
ambiguity and affect––help elucidate how consumers assign risk, 
especially when some information is unknown. 
A. Ambiguity 
Ambiguity is defined as “a quality depending on the amount, type, 
reliability and ‘unanimity’ of information, and giving rise to one’s 
degree of ‘confidence’ in an estimate of relative likelihoods.”15  Daniel 
Ellsberg, the pioneer of the ambiguity theory, questioned the ability to 
predict a particular decision when uncertainty exists.16  In his 
hypothetical experiment, Ellsberg presented subjects with two urns: 
the first urn contained a known mixture of colored balls (fifty percent 
red and fifty percent black) and the second urn contained an unknown 
mixture (although unknown to subjects, it actually contained the same 
percentage).  Subjects would be paid $100 if they selected a red ball 
and $0 if they selected a black ball.17  When asked which urn they 
wished to choose from, subjects preferred choosing from urn one 
(with the known ratio).18  That is, subjects preferred to bet on the urn 
with the known risk rather than the second urn, which contained an 
unknown risk.19  Put differently, subjects tend to prefer to bet on a 
known probability rather than an unknown probability.20  This 
phenomenon, where subjects are more likely to choose a known risk 
 
 15  Ellsberg, supra note 14, at 657. 
 16  Id. at 656. 
 17  Id. at 650. 
 18  Id. at 657. 
 19  Id. at 657–58; see also Laura L. Blaisdell et al., Unknown Risks: Parental Hesitation 
about Vaccination, 36 MED. DECISION MAKING 479, 480 (2016). 
 20  Blaisdell, supra note 19. 
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compared to an unknown risk underscores the theory of ambiguity in 
decision-making.21  Numerous studies have tested this directly or 
indirectly.22  As discussed in greater detail in Part II, this is particularly 
relevant to how consumers perceive risk with new technology, 
especially when all the risks are unknown. 
Research supporting ambiguity in decision-making also focuses 
on how subjects make decisions when uncertainty for the possible 
outcome is not known.23  In other words, if a person is unsure of a 
particular outcome, the state of potential probabilities is ambiguous.24  
Studies have shown that people are averse to ambiguity—which means 
that if the probability of a risk is presented in an ambiguous way, 
subjects tend to be averse to toward the ambiguity.25  For example, 
“[w]hen ambiguity about vaccination risk was caused by salient missing 
information about the risks from vaccination—a child had a high risk 
of being harmed by the vaccine, or no risk at all, but it was impossible 
to find out which—subjects were more reluctant to vaccinate.”26  
Subjects demonstrate aversion to ambiguous information—especially 
when they perceive that they cannot assign a risk to a particular 
outcome.  In other words, consumers may inappropriately assign risk 
when presented with ambiguous information.  Examples of ambiguity 
aversion are discussed in Part II. 
B. Affect 
Affect is defined as “the specific quality of ‘goodness’ or ‘badness’ 
(a) experienced as a feeling state (with our without consciousness) and 
(b) demarcating a positive or negative quality of a stimulus.”27  In other 
words, affect refers to the reliance on a feeling to guide decision-
making.28  That is, the “faint whisper of emotion” guides decision-
making; “[p]leasant feelings motivate actions that people will 
anticipate will reproduce those feelings [and] [u]npleasant feelings 
 
 21  Id. 
 22  See, e.g., id.; Joanna K. Sax & Neal Doran, Food Labeling and Consumer Association 
with Health, Safety and Environment, 44 J. L. MED. & ETHICS 630, 635–37 (2016) 
[hereinafter Sax & Doran]; Colin Camerer & Martin Weber, Recent Developments in 
Modeling Preferences: Uncertainty and Ambiguity, 5 J. OF RISK AND UNCERTAINTY 325, 333–
41 (1992) (describing empirical studies of ambiguity). 
 23  See Camerer & Weber, supra note 22, at 325. 
 24  See id. at 331 (“When a person is not sure what the distribution of probabilities 
is, we call the state probabilities ambiguous.”). 
 25  See id. at 354. 
 26  Id. 
 27  Paul Slovic & Ellen Peters, Risk Perception and Affect, 15 CURRENT DIRECTIONS IN 
PSYCHOL. SCI. 322, 322 (2006) [hereinafter Slovic, Risk Perception and Affect]. 
 28  See id. 
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motivate actions that people will anticipate will avoid those feelings.”29  
Important research by Paul Slovic and others shows that affect impacts 
how subjects correlate perceptions of risks with benefits.30  That is, 
subjects perceive activities that have high benefits as low risk and vice 
versa.  By way of example, in a study conducted by Alhakami and Slovic, 
subjects demonstrated this inverse relationship with pesticide use—, 
i.e., high risk and low benefit.31  These results were linked to how 
subjects viewed the goodness or badness of the activity and assigned 
risk accordingly.32  According to Slovic and Peters, this finding 
demonstrates that “[i]f their feelings toward an activity are favorable, 
they tend to judge the risks as low and the benefits as high; if their 
feelings toward the activity are unfavorable, they tend to make the 
opposite judgment—high risk and low benefit (i.e., the affect 
heuristic).”33  Referring back to the difference of risk perceptions 
regarding nuclear energy (which was discussed in the introduction), 
Slovic and colleagues suggest that affect underscores the reasons why 
the feeling of dread leads people to assign a high risk to exposure to 
radiation from nuclear power plants as compared to exposure to 
radiation from x-rays.34  As noted by Slovic and Peters, “an assessment 
not shared by risk experts.”35 
In decision-making, consumers may not always maximize 
expected utility; rather, they may ask themselves how they feel about a 
particular decision.36  Or, if consumers are experiencing a particular 
feeling at a given time, this emotional state will impact their decision 
processes.37  For example, emotional states such as anger and arousal 
 
 29  Id. 
 30  See id. at 323; Slovic, The Affect Heuristic, supra note 14, at 1333–34. 
 31  Slovic, Risk Perception and Affect, supra note 27, at 323 (referring to study 
conducted by Alhakami and Slovic).  
 32  Id. 
 33  Id. (internal citation omitted). 
 34  Id. 
 35  Id. 
 36  See Paul Slovic, What’s Fear Got to Do with It? It’s Affect we Need to Worry About, 69 
MO. L. REV. 971, 973 (2004) [hereinafter Slovic, What’s Fear Got to Do with It?] (“As life 
became more complex and humans gained more control over their environment, 
analytic tools were invented to ‘boost’ the rationality of our experiential thinking.  
Subsequently, analytic thinking was placed on a pedestal and portrayed as the epitome 
of rationality.  Affect and emotion were seen as interfering with reason.”); Ellen Peters 
et al., Affect and Decision Making: A “Hot” Topic, 19 J. BEHAV. DECISION MAKING 79, 80 
(2006) (“First, affect can act as information: at the moment of judgment or choice, 
decision makers consult their feelings about a choice and ask, ‘How do I feel about 
this?’”). 
 37  Peters et al., supra note 36, at 81–83. 
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impact how subjects make decisions.38  Importantly, feelings come on 
quickly—and this surge can impact decision-making at a particular 
point in time.39  These feelings impact risk assessment.40 
Survival requires that humans assess risk from different situations 
and then either avoid risky situations or design around them.41  In the 
contemporary times, consumers are assessing risk as they are exposed 
to various technologies; but given the complicated nature of 
technology, it can be challenging for a typical consumer to fully 
evaluate and assign risk to a new technology.  “The dominant 
perception for most Americans (and one that contrasts sharply with 
the views of professional risk assessors) is that they face more risk today 
than in the past and that future risks will be even greater than 
today’s.”42  Understanding how consumers assign risk—and what 
underlies this decision-making process—is important for 
implementing and regulating policies that relate to health and safety.43 
C. Ambiguity, Affect and Decision-Making 
Decision-making is a complicated process.  Although it cannot be 
neatly condensed into these two theories—ambiguity and affect—they 
can be (and have been) empirically tested and used to assist with 
understanding consumer perceptions of technology.44  Both of these 
theories can operate at the same time, especially because they both 
apply to perceptions of risk.  In the case of biotechnology, unknown 
risks exist and so we need to understand how consumers perceive and 
weigh those risks. 
In the Internet age, consumers can Google anything and a wide 
variety of information will be presented.  If, for example, a consumer 
 
 38  Id. at 81. 
 39  See Slovic, What’s Fear Got to Do with It?, supra note 36, at 971. 
 40  See id. at 976 (“Evidence of risk as feelings was present (though not fully 
appreciated) in early psychometric studies of risk perception.  Those studies showed 
that feelings of dread were the major determiner of public perception and acceptance 
of risk for a wide range of hazards.”). 
 41  See Slovic, Perception of Risk, supra note 6, at 280. 
 42  Id. 
 43  Id. (“The basic assumption underlying these efforts is that those who promote 
and regulate health and safety need to understand the ways in which people think 
about and respond to risk.”). 
 44  This article does not suggest that other theories and approaches are not also 
involved, but instead advocates that the role of affect and ambiguity are understudied 
in this area.  For other approaches, see, for example, John Bohannon, Government 
‘Nudges’ Prove their Worth, 352 SCI. 1042, 1042 (2016), for a discussion of successful 
government nudges; see also Dan M. Kahan, A Risky Science Communication Environment 
for Vaccines, 342 SCI. 53, 53–54 (2013), for a discussion addressing the role of cultural 
cognition in risk assessment. 
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searches for information regarding vaccinations and autism, websites 
will pop up that promote this linkage.  Despite the scientific consensus 
that vaccinations do not cause autism, the public perception still exists.  
When parents are making a decision as to whether to vaccinate their 
child or not, they are weighing risks.  Consumers may, for example, 
have difficulty assigning risk to vaccinations if they perceive there are 
unknowns (ambiguity) or that vaccinations may hurt their children 
(affect).  Consumers may be subject not only to conflicting 
information, but may also have trouble evaluating whether the source 
is credible.  If one medical professional touts a linkage between 
vaccines and autism, then how do consumers weigh information from 
other medical professionals that no linkage exists? 
The next section turns to examples in biotechnology where 
consumers may have difficulty assigning risk either because the 
information is unknown or because information impacts the feelings 
they experience as they make a decision. 
II.  AREAS OF BIOTECHNOLOGY THAT FACE CONSUMER 
OPPOSITION 
This section addresses some controversial examples of 
biotechnology wherein public calls for regulation or elimination are 
not in accord with the scientific consensus.  The underlying science of 
each area is described in order to guide the discussion regarding what 
risks are known and unknown.  This section will also highlight where 
the controversy about each topic exists. 
A. Vaccines 
The development of vaccines to eradicate disease is considered a 
medical breakthrough.45  Smallpox, polio, measles, mumps, rubella, 
and other diseases that crippled and killed people can now be avoided 
through the use of vaccines.46  Vaccines are widely supported by public 
health officials as a main mechanism to avoid the spread of disease.47  
Vaccines are regarded as safe and effective.48 
 
 45  See Achievements in Public Health, 1900–1999 Impact of Vaccines Universally 
Recommended for Children––United States, 1990–1998, 48 MORBIDITY & MORTALITY WKLY. 
REP. 243, 243–48 (1999), https://www.cdc.gov/mmwr/preview/mmwrhtml/000568 
03.htm (“Vaccines are one of the greatest achievements of biomedical science and 
public health.”). 
 46  See CDC, Why are Childhood Vaccines So Important?, supra note 1. 
 47  See CDC, Why Immunize?, supra note 2. 
 48  Vaccine Safety, CTR. FOR DISEASE CONTROL, http://www.cdc.gov/vaccinesafety/ 
index.html (last updated Nov. 2, 2015) [hereinafter CDC, Vaccine Safety] (“Data show 
that the current U.S. vaccine supply is the safest in history.”). 
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Vaccines are small doses of a dead or attenuated (not able to 
reproduce) virus.  Upon administration of a vaccine, the body’s 
immune system generates an immune response by creating antibodies 
to kill the virus.49  In the case of vaccines, the injected virus is either 
dead or attenuated, so the disease can never manifest but the immune 
reaction is activated nevertheless.50  Once the antibodies are created 
the immune system now has a memory bank, which can be analogized 
to a filing system, as to how to fight that particular virus.51  This is why 
the term “immunized” is used.  Now, if the body ever encounters the 
actual virus through real contact, the immune system can return to its 
files, quickly call up the particular antibody, and efficiently fight off the 
virus before the virus can infiltrate and replicate in the body.52  Put 
differently, vaccines teach the body how to defend against particular 
diseases, if exposed. 
Vaccines are not without any risk.  Patients can have allergic 
reactions or infection at the site of injection.  A National Vaccine Injury 
Compensation Program, established by the US government, 
compensates patients who are injured as a result of vaccines.53  In 
balancing the risk to benefit ratio, the overwhelming response by 
physicians and public health officials is to support vaccine regiments. 
About twenty years ago, a research team published a report in the 
Lancet identifying a connection between vaccines and autism.54  This 
research paper—which later had to be retracted because the data did 
not support the conclusion—still managed to instigate an enormous 
anti-vaccination campaign.  Individuals claimed that the mandatory 
 
 49 See Understanding How Vaccines Work, CTR. FOR DISEASE CONTROL, 
http://www.cdc.gov/vaccines/hcp/conversations/downloads/vacsafe-understand-
color-office.pdf (last visited May 24, 2016) (“Vaccines help develop immunity by 
imitating an infection.  This type of infection, however, does not cause illness, but it 
does cause the immune system to produce T-lymphocytes and antibodies. . . .  Once 
the imitation infection goes away, the body is left with a supply of ‘memory’ T-
lymphocytes, as well as B-lymphocytes that will remember how to fight that disease in 
the future.”).  
 50  See, e.g., id. (describing live, attenuated viruses and inactivated viruses). 
 51  See, e.g., id. (describing the five main types of vaccines commonly administered). 
 52  Id. (“Once the imitation infection goes away, the body is left with a supply of 
‘memory’ T-lymphocytes, as well as B-lymphocytes that will remember how to fight that 
disease in the future.”).  
 53  See National Vaccine Injury Compensation Program, HEALTH RES. & SERVS. ADMIN., 
http://www.hrsa.gov/vaccinecompensation/ (last updated Feb. 2016).  
 54  A.J. Wakefield et al., Ileal-Lymphoid-Docular Hyperplasia, Non-Specific Colitis, and 
Pervasive Developmental Disorder in Children, 351 THE LANCET 637, 637–41 (1998), 
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)11096-0.pdf. 
It is critical to note, however, that this misleading publication was subsequently 
retracted. 
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vaccination programs violated parental autonomy—especially given 
the concerns about the link between vaccines and autism.  Despite the 
retraction of the Lancet paper and many dozens of studies 
demonstrating that vaccines are not linked to autism, this view that 
vaccines cause autism persists.  An Internet search for “vaccines and 
autism” provides results that can tell a parent anything that s/he wants 
to believe, regardless if it is based on scientific evidence.  Put 
differently, despite scientific evidence that vaccines are not linked to 
autism, consumers may still read information on the Internet that says 
otherwise.55 
Both individual and religious objections to vaccines led to the 
passage of state laws exempting children from mandatory vaccination 
requirements.  Most notably, California was at the forefront of the 
individual exemptions.  Over time, more and more children stopped 
receiving vaccines.  In 2014, a major measles outbreak at Disneyland in 
southern California called attention to the dangerous realities that can 
occur when people stop being vaccinated.56  Public health officials 
believe that due to vaccination exemptions, an outbreak occurred.  
This is particularly troubling for parents who cannot vaccinate their 
children for medical reasons and rely on the requisite level of herd 
immunity.57  In response to this outbreak, on June 30, 2015, California 
Governor Jerry Brown signed SB277, which removed the individual 
exemptions for children, leaving only a medical exemption.58 
Laura Blaisdell and colleagues conducted an insightful study by 
interviewing focus groups to understand why parents might be hesitant 
or reject vaccinating their children.59  A number of themes were 
 
 55  See, e.g., Whet Moser, Why Do Affluent, Well Educated People Refuse Vaccines?, 
CHICAGO (Mar. 26, 2014), http://www.chicagomag.com/city-life/March-2014/Why-Is-
Vaccine-Refusal-More-Prevalent-Among-the-Affluent/ (“Social networks (actual ones) 
seem to be incredibly important in forming opposition to vaccines, either in whole or 
in part: ‘in this study, parents who didn’t follow CDC guidelines were more likely to 
have extensive “source networks” that included books, blogs, websites, and magazine 
articles to which they turned for vaccine-related information.’”). 
 56  Measles, CAL. DEP’T OF PUB. HEALTH, https://www.cdph.ca.gov/HEALTHINFO 
/DISCOND/Pages/Measles.aspx (last updated Feb. 2, 2016).  
 57  See, e.g., NICOLE HUBERFELD, ELIZABETH WEEKS & KEVIN OUTTERSON, THE LAW OF 
AMERICAN HEALTH CARE 1, 12–13 (2016). 
 58  See Letter from Jerry Brown, Governor, State of Cal., to Members of Cal. State 
Senate (June 30, 2015), https://www.gov.ca.gov/docs/SB_277_Signing_Message.pdf; 
see also Editorial, California Settles the Vaccination Question, L.A. TIMES (June 30, 2015, 
2:43 PM), http://www.latimes.com/opinion/editorials/la-ed-vaccination-bill-signed-
into-law-in-california-20150701-story.html (“With Gov. Jerry Brown’s swift signature 
Tuesday on a tough new mandatory vaccination bill, the state has established itself as 
a national leader on public health.”).  
 59  Blaisdell, supra note 19, at 479–80. 
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confirmed and elucidated among Vaccine Hesitant Parents (VHPs).60  
First, VHPs expressed that the risks associated with vaccinations or non-
vaccinations are unknown, and that the long-term risks associated with 
vaccinations are similarly unidentified, including for example, linkage 
to ailments and diseases.61  Blaisdell and colleagues learned that VHPs 
who perceived vaccinations as risky stated that they were fearful of 
additives, the permanency of the decision, and that their infants were 
too young to process the vaccination.62  These parents also perceived 
the risk of contracting a vaccine-preventable disease as low, and based 
their perception on low-risk environments, low-severity of disease, and 
healthy environments.63  When pressed about what the parents would 
do if their child was exposed to a vaccine-preventable disease, they 
responded that they would promptly be able to detect, obtain 
treatment, or even treat the disease themselves.64  In some cases, they 
expressed that the symptoms and treatment of diseases were known 
qualities, which suggested they could assign a risk to known attributes.65 
Within the VHP focus groups, some decided to either delay 
vaccination, change the vaccination schedule, or refuse vaccination 
altogether, thus a spectrum of perceived risks was found.66  The quotes 
from the VHP participants are particularly illustrative of how VHPs 
perceive risk, especially when there are unknowns; a sampling of which 
is reproduced here:67 
 “We don’t know the long term side effects of some of 
these things.  A doctor can’t tell me ‘Oh there’s no 
long-term side effects’. . . because [they] don’t know.  
It stays in your body forever, and there’s all sorts of 
things going on that we can’t attribute to any 
particular thing.  Who’s to say it’s not [vaccination], 
because we can’t see the link?” 
 “One of the scary things about vaccines is that once 
it’s done, it’s done.  You can’t undo it.  So you know 
I have this kid and maybe or maybe not vaccines have 
an effect on his progression in his life at this point.” 
 
 60  Id. at 480, 485–87. 
 61  Id. at 481–83. 
 62  Id. 
 63  Id. at 483–84. 
 64  Id. at 484. 
 65  Blaisdell, supra note 19, at 484 (“I think that now if you can catch something, 
all these dreadful diseases, if you rush to the hospital right away they can probably save 
your life.  So I’d rather go with that and see if something happens and then go that 
way [vaccinate].”). 
 66  See id. at 485–87. 
 67  Id. at 483–85. 
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 “We don’t send them to any daycares.  I felt like they 
weren’t exposed to a lot of different kids all day long, 
or for long periods of time without me around 
watching them and keeping them safe.  It doesn’t 
mean they are not gonna get a disease, it also means 
that they have a less chance.” 
 “I think that now if you catch something, all these 
dreadful diseases, if you rush to the hospital right 
away they can probably save your life.  So I’d rather 
go with that and see if something happens then go 
that way [vaccinate].”68 
Blaisdell and colleagues utilized the ambiguity decision-making 
theory not only to categorize the reasoning of the VHPs, but also 
suggest that understanding how VHPs assign risk can be used to 
educate and address individual concerns.69 
Interestingly, the largest group of anti-vaccine advocates turns out 
to be upper-middle class white women.70  It is unclear why this group, 
specifically, questions the validity and safety of vaccines, but some 
hypothesize that they are merely less trusting of medical authorities 
generally.71  Another reason could be the luxury of wanting to return 
to a more wholesome state when things were simpler—we see this with 
food choices, homeopathic treatments, and avoiding the “poisons” in 
vaccinations.72 
While the Blaisdell study nicely categorizes the responses by VHPs 
into risk perceptions based on ambiguity, many of the responses 
suggest affect could play a role in risk perception.  If VHPs perceive 
that a vaccine will harm their child, they will feel “badness” about 
making a decision to vaccinate.  Or, conversely, a VHP may experience 
“goodness” of refusing a vaccine because s/he perceives they have 
averted a high-risk situation.  This scenario nicely fits into Slovic and 
colleagues’ theory that when a subject views the risk as high, they also 
view the benefit as low.73 
 
 68  Id. 
 69  Id. at 479–80. 
 70  Id. 
 71  Moser, supra note 55 (“Parents whose children have been exempted from 
vaccinations have, unsurprisingly, less trust in a long list of authorities, from health 
care professionals to the CDC.”).  
 72  See, e.g., Rachel Dunlop, 9 Vaccination Myths Busted. With Science!, MAMAMIA (Nov. 
12, 2011), http://www.mamamia.com.au/vaccination-myths-busted-by-science-cheat-
sheet-on-immunisation/ (discussing vaccination myths); see also Renee Shaw Hughner 
et al., Who are Organic Food Consumers? A Compilation and Review of Why People Purchase 
Organic Food, 6 J. CONSUMER BEHAV. 94, 101–03 (2007). 
 73  Slovic, Risk Perception and Affect, supra note 27, at 323 (see citation therein). 
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If the VHPs existed in a vacuum, the discussion might simply turn 
to a debate about whether parents are harming their children by 
refusing to vaccinate.  But, the problem with allowing individuals to 
opt-out of vaccinating their children is that it has a ripple effect.  To 
be effective in group settings, such as school classrooms, the 
compliance rate with vaccinations needs to be at a level to achieve the 
requisite herd immunity.  California, for example, now requires that 
children attending preschool and public school be vaccinated absent 
a medical contraindication.74  It is possible that consumers also have an 
affective response to the term “mandatory.” 
An important policy issue is how to educate the VHPs so that they 
can appropriately assign risk and make an informed decision.  Simply 
providing VHPs with the scientific consensus is probably not enough; 
otherwise, we would likely not see this problem manifesting, especially 
among college-educated women.  Another policy concern is 
differentiating for VHPs the existing knowledge about vaccines as 
compared to other areas whether medical professionals have had to 
backtrack, such as with nutritional recommendations.  Part III explores 
various options to address this issue. 
B. GMOs 
Genetically Modified Organisms (GMOs) are the subject of major 
public debate.75  Although the term genetically engineered (GE) food 
is a better term to describe this sector of the food supply, this article 
will use the colloquial term GMO.  GMOs, collectively, are foods that 
have been altered through the application of biotechnology.  GMOs 
are a more precise application of genetic engineering compared to 
conventional breeding. 
Our entire food supply is genetically modified.76  Conventional 
breeding utilizes several techniques to obtain desired characteristics.77  
 
 74  S.B. 277, 2015–16 Reg. Sess. (Cal. 2015); see also Tara Haelle, California 
Vaccination Bill SB 277 Signed By Governor, Becomes Law, FORBES (June 30, 2015, 2:14 
PM), http://www.forbes.com/sites/tarahaelle/2015/06/30/california-vaccination-
bill-sb-277-signed-by-governor-becomes-law/#6091044a1233.  
 75  William Saletan, Unhealthy Fixation: The War Against Genetically Modified 
Organisms is Full of Fearmongering, Errors, and Fraud. Labeling Them Will Not Make You 
Safer, SLATE (July 15, 2015, 5:45 AM), http://www.slate.com/articles/health_and 
_science/science/2015/07/are_gmos_safe_yes_the_case_against_them_is_full_of_fra
ud_lies_and_errors.html. 
 76  Sax & Doran, supra note 22, at 630; cf. Saletan, supra note 75. 
 77  R. Panda et al., Challenges in Testing Genetically Modified Crops for Potential Increases 
in Endogenous Allergen Expression for Safety, 68 ALLERGY: EUR. J. ALLERGY & CLINICAL 
IMMUNOLOGY 142, 142 (2013), http://onlinelibrary.wiley.com/doi/10.1111/all.12076 
/pdf. 
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Conventional tactics such as selective breeding, x-rays, and chemical 
mutagenesis are employed to create and select for an “improved” 
domestic crop or animal.78  The genetic modifications using 
conventional methods, along with seed selection by commercial 
breeders, have proved—over hundreds of years—to be safe, and food 
created through conventional methods easily enters the marketplace.79 
Despite misperceptions of some of the public, organic food is also 
genetically modified, but through conventional methods.80  Organic 
farmers are growing domesticated crops selected for desired traits.  
The term “organic” does not refer to whether the crop has genetic 
advantages through selective breeding.81  Put differently, we are not 
eating wild-type varieties; we are eating domesticated crops that are 
genetically modified. 
The technology to create food from GMOs is a precise mechanism 
to accomplish what we already do in our food supply.82  Unlike 
conventional breeding techniques, genetic engineering techniques 
allow for a precise modification to obtain a desired trait.  In 
conventional breeding techniques, to obtain a desired trait, the seed 
may also carry hundreds to thousands of other mutations––most of 
which are never characterized.83  In other words, genetic engineering 
 
 78  See, e.g., Gregory Conko et al., A Risk-Based Approach to the Regulation of Genetically 
Engineered Organisms, 34 NATURE BIOTECHNOLOGY 493, 494 (2016) (internal citations 
omitted) (“When plant breeders have exhausted the genetic resources (germ, plasm) 
within their crop’s species, they have employed several techniques, such as 
mutagenesis and wide-cross hybridization, to introduce new genes or alleles into their 
cultivars.  By the middle of the past century, X-ray and other mutagens were being 
used routinely and at scale to obtain a range of genetic changes, from point mutations 
to translocations in interspecific hybrids; the latter allowed pieces of chromosomes 
from wild species to integrate or translocate onto crop chromosomes.  Mutation 
breeding is now routinely accomplished with other sources of ionizing radiation and 
with mutagenic chemicals.”).  
 79  See id. at 494 (“Nevertheless, such ‘non-recombinant DNA transgenic varieties’ 
(as they might be called) have been introduced safely into commercial cultivation 
around the world for more than a half-century without the need for premarket 
regulatory approvals.”). 
 80  See, e.g., David Newland, Sorry Hipsters, That Organic Kale is a Genetically Modified 
Food, SMITHSONIAN.COM (Sept. 10, 2014), http://www.smithsonianmag.com/science/ 
sorry-hipsters-organic-kale-genetically-modified-food-180952656/?no-ist. 
 81  See generally Organic Agriculture, U.S. DEP’T OF AGRIC., 
http://www.usda.gov/wps/portal/usda/usdahome?contentidonly=true&contentid=o
rganic-agriculture.html (last updated Jan. 9, 2015) (describing organic agriculture). 
 82  Steven H. Strauss & Joanna K. Sax, Ending Event-Based Regulation of GMO Crops, 
34 NATURE BIOTECHNOLOGY 474, 476 (2016) [hereinafter Strauss & Sax]. 
 83  See Conko et al., supra note 78, at 494 (internal citation omitted) (“Many crops 
contain genes crossed in from wild relatives that have no history of safe use and that 
may even be known to produce toxins or allergens.  In wide-cross hybridization, the 
genes or alleles of interest are moved into the crop—along with countless other 
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technology allows scientists to obtain desired traits with less genetic 
mutations.84 
In the 1980s, the Food and Drug Administration (FDA) expressed 
concerns about increased expression levels of endogenous toxins or 
allergens that may result from genetic engineering techniques.85  This 
is because changes to the genetic profile can increase or decrease the 
expression of other genes.86  Since then, many dozens of studies have 
demonstrated that technology used to create GMO crops does not lead 
to the mass destabilization of genome expression that the FDA was 
worried about.87 
Many decades of research demonstrate that plant genomes are 
highly unstable, with many epigenetic events occurring over time.88  
Gene expression profiles cannot be captured at any one time, given 
the widespread changes.89  Transpositions are often occurring, which 
will shake up the genetic sequence.90  Due to the high plasticity of plant 
 
genetic changes of unknown function, including those that potentially could alter the 
weediness of the plants or the allergenicity, toxicity or nutritional value of foods 
derived from them.”).  
 84  Cf. Strauss & Sax, supra note 82, at 475. 
 85  Statement of Policy – Food Derived from New Plant Varieties, Guidance to 




 86  Id. (“DNA segments introduced using the new techniques insert semi- randomly 
into the chromosome, frequently in tandem multiple copies, and sometimes in more 
than one site on the chromosome.  Both the number of copies of the gene and its 
location in the chromosome can affect its level of expression, as well as the expression 
of other genes in the plant.”).  
 87  Strauss & Sax, supra note 82, at 475 (2016) (citing R.A. Herman & W.D. Price, 
Unintended compositional changes in genetically modified (GM) crops: 20 years of research, 61 
J. AGRIC. FOOD CHEM. 11695–701 (2013); H.Y. Steiner et al., Editor’s choice: Evaluating 
the potential for adverse interactions within genetically engineered breeding stacks, 161 PLANT 
PHYSIOLOGY 1587, 1587–94 (2013), https://www.ncbi.nlm.nih.gov/pmc/articles/PM 
C3613440/pdf/1587.pdf; A.E. Ricroch, Assessment of GE food safety using ‘-omics’ 
techniques and long-term animal feeding studies, 30 NATURE BIOTECHNOLOGY 349, 349–54 
(2013); J. Schnell et al., A comparative analysis of insertional effects in genetically engineered 
plants: considerations for pre-market assessments, 24 TRANSGENIC RES. 1, 1–17 (2015), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274372/). 
 88  Strauss & Sax, supra note 82, at 476 (“These studies show evidence of far greater 
structural, epigenetic and gene-expression variation than had been expected, in 
general, far exceeding those imparted by genetic engineering (e.g., refs. 
11,24,25,26).”). 
 89  Id. at 476 nn.22 & 24 (“Gene insertion appears to be a small impact by 
comparison to the ongoing dynamic variation in gene and genome structure during 
evolution and breeding.”). 
 90  Id. (“Extensive transposition, where genes and promoters are moved 
throughout genomes, and normal mutational processes and DNA repair, provide a 
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genomes, precise genetic changes, particularly at a single base pair 
level, create a risk of the increased expression of toxic or allergenic 
proteins that is close to zero.91  Put differently, if the more widespread 
changes to plant genomes through conventional breeding does not 
increase the expression of toxic of allergenic proteins, then the less 
invasive and more precise technology used to create food from GMOs 
should not and does not create greater risk in this area. 
The public is heavily weighing in on our food supply—calling for 
more nutritious food, sustainable farming, and safety.  This call for 
health, safety, and the environment is manifesting itself through 
labeling laws.92  People want to know what they are eating. 
The problem with labeling laws—labeling food as GMO, non-
GMO, organic, etc.—is that the laws do not tell the consumer about 
the health, safety, or environmental friendliness.  Decades of research 
demonstrate that food from GMOs is as safe as conventional food.93  
 
continual source of potential novelty in the kinds and degrees of modification of gene 
expression throughout the genome.”). 
 91  Id. (“Thus, the risk of unintended expression of endogenous toxic proteins 
from genetic engineering is no greater than conventional breeding, and in most cases 
far less.”); see also Conko et al., supra note 78, at 493–99. 
 92  See, e.g., S. Res. 764, 114th Cong. (2016) (enacted) (amending the Agricultural 
Marketing Act of 1946, 7 U.S.C. 1621 (2012)); H.R. Res. 1599, 114th Cong. (2016) 
(enacted).  See also An Act Relating to the Labeling of Food Produced with Genetic 
Engineering, VT. STAT. ANN. tit. 9, §§ 3040, 3041 (2014) (effective July 1, 2016); Press 
Release, Mike Pompeo, U.S. Congressman, Pompeo Applauds Passage of Safe and 
Accurate Food Labeling Act (July 23, 2015), http://pompeo.house.gov/news/ 
documentsingle.aspx?DocumentID=398519. 
 93  Chelsea Snell et al., Assessment of the Health Impact of GM Plant Diets in Long-term 
and Multigenerational Animal Feeding Trials: A Literature Review, 50 FOOD & CHEMICAL 
TOXICOLOGY 1134, 1145 (2012); Pamela Ronald, Plant Genetics, Sustainable Agriculture 
and Global Food Security, 188 GENETICS 11, 12 (2011); Press Release, American 
Association for the Advancement of Science, Statement by the AAAS Board of 
Directors on Labeling of Genetically Modified Foods (Oct. 20, 2012), 
http://www.aaas.org/sites/default/files/migrate/uploads/AAAS_GM_statement.pdf 
[hereinafter Statement by AAAS]; Yan Song et al., Immunotoxicological Evaluation of Corn 
Genetically Modified with Bacillus thuringiensis Cry1Ah Gene by a 30-day Feeding Study in 
BALB/c Mice, 9 PLOS ONE 1, 10 (Feb. 10, 2014), http://www.plosone.org/article/info 
%3Adoi%2F10.1371%2Fjournal.pone.0078566; Yanfang Yuan et al., Effects of 
Genetically Modified T2A-1 Rice on the GI Health of Rats After 90-day Supplement, 3 SCI. REP. 
1, 6–7 (June 11, 2013), http://www.nature.com/srep/2013/130611/srep01962/pdf/ 
srep01962.pdf; Xueming Tang et al., A 90-Day Dietary Toxicity Study of Genetically 
Modified Rice T1C-1 Expressing Cry1C Protein in Sprague Dawley Rats, 7 PLOS ONE 1, 6 
(Dec. 27, 2012), http://www.plosone.org/article/info%3Adoi%2F10.1371%2F 
journal.pone.0052507.  See also Philip D. Brune et al., Safety of GM Crops: Compositional 
Analysis, 1 J. AGRIC. & FOOD CHEMISTRY 8243, 8245 (2013); William D. Price & Lynne 
Underhill, Application of Laws, Policies, and Guidance from the United States and Canada to 
the Regulation of Food and Feed Derived from Genetically Modified Crops: Interpretation of 
Composition Data, 1 J. AGRIC. FOOD & CHEMISTRY 8349, 8353 (2013); Declan Butler, 
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Consumers might be surprised to learn that food labeled “organic” 
does not have a higher safety profile than other types of food and, in 
some cases, it actually has a lower safety rating.94  This is because 
organic farmers use manure as fertilizer, which, when mishandled, 
creates major safety concerns.  Consumers are worried about exposure 
to pesticides and herbicides, although scientific studies are clear that 
low-level exposure to the most commonly used pesticides and 
herbicides creates no risk to human health.95  The environmental 
concerns are more difficult to address not because something is GMO, 
non-GMO or organic, but because farming is inherently non-eco-
friendly.96  The sustainability component is much more nuanced than 
labeling can tell a consumer. 
To understand consumer decision-making, a survey aimed at 
consumer associations of health, safety, and environmental 
friendliness with various labels and types of food was conducted.97  
Subjects were asked to rank how healthy, safe, and environmentally-
friendly various food products with the labels “organic,” “natural,” “low 
fat or fat free,” “non-GMO” and “GMO” were compared to each 
other.98  The results showed that respondents found all labels to be 
significantly healthier, safer, and environmentally friendly compared 
to the label “GMO.”99  In other words, the subjects found the label 
“GMO” to be associated with less healthy, less safe, and less 
environmentally friendly food products compared to other labels.100 
The results of this study provide a number of interesting 
 
Hyped GM Maize Study Faces Growing Scrutiny, NATURE INT’L WKLY. J. SCI. (Oct. 10, 2012), 
http://www.nature.com/news/hyped-gm-maize-study-faces-growing-scrutiny-1.11566 
(rejecting paper that found adverse health events in rats fed GM corn). 
 94  Mischa Popoff et al., Organics versus GMO: Why the debate?, GENETIC LITERACY 
PROJECT (Oct. 15, 2013), http://www.geneticliteracyproject.org/2013/10/15/ 
organics-versus-gmo-why-the-debate/; A. Mukherjee et al., Preharvest Evaluation of 
Coliforms, Escherichia coli, Salmonella, and Escherichia coli O157:H7 in Organic and 
Conventional Produce Grown by Minnesota Farmers, 67 J. FOOD PROTECTION 894, 894–900 
(2004). 
 95  See, e.g., Food and Pesticides, ENVTL. PROTECTION AGENCY, 
https://www.epa.gov/safepestcontrol/food-and-pesticides (last updated Mar. 15, 
2016); G.M. Williams et al., Safety Evaluation and Risk Assessment of the Herbicide Roundup 
and Its Active Ingredient, Glyphosate, for Humans, 31 REG. TOXICOLOGY & PHARMACOLOGY 
117, 117 (2000) (“Roundup herbicide does not pose a health risk to humans.”). 
 96  See Henry I. Miller, Why Organic Isn’t ‘Sustainable’, FORBES (Nov. 19, 2014), 
http://www.forbes.com/sites/henrymiller/2014/11/19/why-organic-isnt-
sustainable/2/#9166d235aed9.  
 97  Sax & Doran, supra note 22, at 630–38. 
 98  Id. at 633. 
 99  Id. at 634–35. 
 100  Id. 
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observations.  First, the label “natural” has no regulatory definition.101  
Despite this, respondents associated the label “natural” with health, 
safety, and environmental friendliness.102  Second, the scientific 
consensus is that food from GMOs is as safe as conventional food.  The 
results demonstrate a consumer disconnect with scientific consensus, 
and suggest that it is important to undertake studies to understand 
why.  Finally, the results suggest that additional studies are needed to 
understand why consumers inappropriately assign risk to food labeled 
as GMO.103 
Affect and ambiguity might help explain consumer perceptions 
of food created from GMOs.  If consumers perceive food created from 
GMOs as less safe, less healthy or less environmentally friendly, then 
they might experience a feeling of “badness” when purchasing or 
eating this food.104  Conversely, consumers may experience “goodness” 
when buying food that they believe is safe, healthy, and 
environmentally friendly, such as organic food.  In other words, 
consumers will want to make decisions that reproduce pleasant 
feelings, and consumers may be more likely to buy food that satisfies 
their affective tendencies.105  Similarly, when consumers feel as though 
they do not understand GMO technology, they will be unable to assign 
risk to food created by this technology.  Additionally, consumers may 
have trouble evaluating information in the face of conflicting 
information from apparently credible sources.  In the end, consumers 
might rather buy conventional food because they can assign a risk to 
that food, than buy food from GMOs where they perceive that they 
cannot assign a risk. 
Policymakers need to address the multitude of problems facing 
our food supply.  Scientific advances have often been the solution to 
problems.  From a scientific perspective, genetic engineering provides 
an important avenue to solve food supply issues and address 
environmental concerns.  It would be interesting to determine the 
outcome if consumers were told that conventional food contains 
hundreds to thousands of unknown and uncharacterized mutations 
(which is true), and whether they would still feel as confident in 
choosing non-GMO over GMO.  These types of issues will be explored 
 
 101  Id. at 635. 
 102  Id. at 634–35. 
 103  Sax & Doran, supra note 22, at 634–35. 
 104  Id. 
 105  See Slovic, Risk Perception and Affect, supra note 27, at 322 (“Many theorists have 
given affect a direct and primary role in motivating behavior.  Pleasant feelings 
motivate actions that people anticipate will reproduce those feelings.  Unpleasant 
feelings motivate actions that people anticipate will avoid those feelings.”). 
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in Part III. 
C. rbST 
Recombinant bovine somatotrophin (rbST) is the injection of a 
naturally occurring bovine growth hormone, to increase milk 
production in cows.106  Two areas of scientific research converged to 
establish this technique.  First, recombinant DNA (rDNA) technology 
allows scientists to create genes in a laboratory and then produce the 
proteins therefrom in a bacteria culture.107  The produced protein is 
then purified and the result is the man-made version of an otherwise 
naturally occurring protein.  Second, research demonstrated that 
injecting bovine growth hormone into cows increased their milk 
production.108  This bovine growth hormone (bGH or bST) is naturally 
produced by the pituitary gland.109  By combining these two areas of 
research, scientists demonstrated that bGH—also referred to as bovine 
somatotropin or Sometribove––created through rDNA could be 
injected into dairy cows to increase milk production.110  The 
recombinant forms of the bGH are referred to as rbGH or rbST.111 
Growth hormones, while naturally occurring in mammals, are 
tightly regulated within a naturally occurring system.112  The concern 
expressed about rbST is whether it has adverse health events in 
 
 106  Lorna Aldrich & Noel Blisard, Consumer Acceptance of Biotechnology Lessons from 
the rbST Experience, 747–01 CURRENT ISSUES IN ECON. OF FOOD MKTS. 1, 1 (1998), 
https://naldc.nal.usda.gov/download/34230/PDF  (“[L]aboratory-produced rbST, 
when injected into cows, increases their milk production.”). 
 107  Anthony J.F. Griffiths, Recombinant DNA Technology, ENCYCLOPEDIA BRITANNICA, 
http://www.britannica.com/science/recombinant-DNA-technology (last updated 
Apr. 8, 2016). 
 108  Bovine Somatotropin, ANIMAL & PLANT HEALTH INSPECTION SERVS. (May 2003), 
https://www.aphis.usda.gov/animal_health/nahms/dairy/downloads/dairy02/Dairy
02_is_BST.pdf (“Repeated studies have demonstrated that administering bST to 
lactating dairy cattle significantly increases milk production.”). 
 109  See Aldrich & Blisard, supra note 106, at 1 (“BST is a bovine growth hormone 
that occurs naturally in cows[.]”); see also Is Milk from rbGH-Injected Cows Safe? Why Isn\’t 
It Labeled?, UCBIOTECH.ORG, http://ucbiotech.org/answer.php?question=37 (last 
updated Feb. 16, 2012) [hereinafter Is Milk from rbGH-Injected Cows Safe?] (“bGH, 
produced in the pituitary glands of dairy cows, is a naturally occurring protein 
hormone in milk, which stimulates the liver to produce insulin-like growth factor-I 
(IGF-I).”). 
 110  Report on the Food and Drug Administration’s Review of the Safety of Recombinant 
Bovine Somatotropin, U.S. FOOD AND DRUG ADMIN., 
http://www.fda.gov/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/uc
m130321.htm (last updated July 28, 2014) [hereinafter FDA Report on rBST]. 
 111  See, e.g., Is Milk from rbGH-Injected Cows Safe?, supra note 109. 
 112  See, e.g., Nathalie Girard et al., Differential in vivo Regulation of the Pituitary Growth 
Hormone-Releasing Hormone (GHRH) receptor by GHRH in Young and Aged Rats, 140 
ENDOCRINOLOGY 2836, 2836 (1999). 
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humans and cows.113  Through extensive FDA evaluation and decades 
of research, it has been shown that “bGH is biologically inactive in 
humans even if injected, rbGH is orally inactive, and bGH and rbGH 
are biologically indistinguishable.”114 
In recent years, consumers have been pulled into a medley of 
debates and concerns among manufacturers.  Some manufacturers are 
utilizing an “rbST-free” label.115  Monsanto, the big agriculture giant, 
has sued over this type of labeling—presumably because the label 
indicates that something is rbST-free because there are health 
concerns to avoid.116  Attorneys for Monsanto argued that the FDA 
recommended that these types of labels be provided in the proper 
context; for example, “no significant difference has been shown 
between milk derived from (hormone)-treated and non-(hormone)-
treated cows.”117  If, however, a consumer wants to find a negative take 
on rbST, they can be led to Organic Valley’s website to obtain 
information about the use of rbST.118 
The labeling debate is indicative of the array of information that 
consumers receive.  If consumers want to learn about the contours of 
rbST, they will find a broad array of information—some correct, some 
 
 113  See Is Milk from rbGH-Injected Cows Safe?, supra note 109. 
 114  FDA Report on rBST, supra note 110. 
 115  See, e.g., ORGANIC VALLEY, https://www.organicvalley.coop/why-organic-
valley/5-reasons-eat-organic/because-our-cows-and-kids-should-grow-their-own-pace/ 
(last visited Jan. 12, 2017) (citing On the Offense, GRACE COMM. FOUND., 
http://www.sustainabletable.org/797/rbgh (last visited Nov. 23, 2016)).  But see 
Background on the Public Hearing on the Labeling of Food Made from the AquAdvantage 
Salmon, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Food/GuidanceRegulation/ 
GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm222608.htm 
(last updated Nov. 19, 2015) (internal citation omitted) (“For example, recombinant 
Bovine Somatotropin (“rBST”) is a synthetic growth hormone that increases milk 
production in dairy cows.  Because FDA found that there was no material difference 
between milk from rBST-treated cows and milk from non-rBST-treated cows, FDA did 
not have the authority to require additional labeling of milk from rBST-treated 
cows.”).  
 116  Susan Q. Stranahan, Monsanto vs. the Milkman, MOTHER JONES (Jan/Feb 2004), 
http://www.motherjones.com/politics/2004/01/monsanto-vs-milkman (“Oakhurst’s 
labels, contends Monsanto, might cause consumers to question the drug’s safety, even 
though the FDA has found that milk from cows injected with rBGH is the same as 
regular milk and that the hormone poses no human health risks.”). 
 117  Matt Wickenheiser, Oakhurst Sued by Monsanto Over Milk Advertising: Monsanto 
Objects to the Dairy’s Public Stance Against Using Hormones, PORTLAND PRESS HERALD, July 
8, 2003, at 1A; see also Bovine Somatotropin, WIKIPEDIA, https://en.wikipedia.org/wiki/ 
Bovine_somatotropin (last visited May 25, 2016). 
 118 Recombinant Bovine Growth Hormone (rBGH): What is it?, ORGANIC VALLEY, 
http://organicvalley.custhelp.com/app/answers/detail/a_id/152/kw/rbst/session/
L3RpbWUvMTQ2NDE5NjQzNS9zaWQvSktQbHVvUm0%3D (last visited July 21, 
2016) (providing reasons why rBGH is bad for cows, people, and farmers). 
SAX (DO NOT DELETE) 2/16/2017  2:44 PM 
456 SETON HALL LAW REVIEW [Vol. 47:433 
wrong, and some contradictory.  Consumers might learn that some 
data indicates that cows treated with rbST also have elevated levels of 
insulin-like growth factor-1 (IGF-1), which can be absorbed in a human 
gut.119  The increased exposure of IGF-1 in humans raises concerns 
about increased levels of cancer.  Thus, the association of rbST and 
IGF-1 continues to be promoted as a possible adverse consequence for 
people who drink milk from cows treated with rbST.120  Studies show 
that milk consumption, whether from cows treated with rbST or not, 
appears to be correlated with increased levels of IGF-1, but no scientific 
consensus exists regarding causation.121 
The Center for Food Safety, an apparent activist group, has 
portions of its website dedicated to rbST.122  The Center for Food Safety 
uses a child drinking a glass of milk to not-so-quietly hint about rbST 
concerns.123  The Center for Food Safety alleges that cows treated with 
rbST may also then need antibiotic treatment for the side effects, 
which subsequently create residues in milk that “can cause allergic 
reactions in sensitive individuals and contribute to the growth of 
antibiotic resistant bacteria, further undermining the efficacy of some 
antibiotics in fighting human infections.”124 
While the Center for Food Safety’s representation has a hint of 
truth, the discussion is more nuanced than how it is presented.  A 
major area of scientific concern is with the health of the cows.125  
 
 119  FDA Report on rBST, supra note 110. 
 120  ORGANIC VALLEY, https://www.organicvalley.coop/why-organic-valley/5-
reasons-eat-organic/because-our-cows-and-kids-should-grow-their-own-pace/ (last 
visited Jan. 12, 2017) (click on “Read the Report” under the statement: “Artificial 
hormone (rBGH / rBST) injections in cows: inhumane and unnecessary”). 
 121  Recombinant Bovine Growth Hormone, AM. CANCER SOC’Y, 
http://www.cancer.org/cancer/cancercauses/othercarcinogens/athome/recombin
ant-bovine-growth-hormone (last updated Sept. 10, 2014) (“The evidence for potential 
harm to humans is inconclusive.”); see also FDA Report on rBST, supra note 110 (“It 
bears repeating that the assumptions that milk levels of IGF-I are increased following 
treatment with rbGH and that biologically active IGF-I is absorbed into the body are 
not supported by the main body of science.  Careful analysis of the published literature 
fails to provide compelling evidence that milk from rbGH-treated cows contains 
increased levels of IGF-1 compared to milk from untreated cows.  Despite recent 
studies that demonstrate that milk proteins protect IGF-I from digestion, the vast 
majority of the published work indicates that very little IGF-I is absorbed following 
ingestion.”). 
 122  About rbGH, CTR. FOR FOOD SAFETY, http://www.centerforfoodsafety.org/issues/ 
1044/rbgh/about-rbgh (last visited May 25, 2016). 
 123  Id. 
 124  Id. 
 125  I.R. Dohoo et al., A Meta-Analysis Review of the effect of Recombinant Bovine 
Somatotropin, 2. Effects on animal Health, Reproductive Performance and Culling, 67 THE 
CANADIAN J. OF VETERINARY RES. 252, 253 (2003). 
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Treatment with rbST is associated with mastitis, which is an infection 
of the breast tissue.126  Treatment of mastitis includes the use of 
antibiotics.127 
The array of information regarding rbST creates challenges for 
consumers to appropriately assign risk to this application of 
biotechnology.  If consumers perceive that treatment of cows with rbST 
causes cancer in humans, then consumers will assign a high risk.  
Likewise, if consumers perceive that children will be harmed by 
drinking milk from cows treated with rbST, then they will experience 
“badness” with an associated decision.  The varying information on the 
Internet about rbST creates issues for consumer decision-making 
because consumers may not be able to appropriately assign risk. 
The rbST and GMO debates underscore the need for a robust 
discussion about how we use science to improve our food supply and 
agriculture techniques.  If consumers have concerns, they should be 
addressed.  It is important, however, that the concerns and assignment 
of risk are based on accurate information.  If information is lacking, 
studies in these areas should be initiated.  In Part III, below, this article 
proposes studies aimed at understanding if and how consumers are 
responding to conflicting information on the Internet. 
D. Fluoridated Water 
Touted as one of the greatest public health achievements in the 
20th Century, fluoridated water significantly decreases cavities, tooth 
decay and tooth loss in children and adults.128  Fluoridated water refers 
to the addition of fluoride to the public water supply.  Tooth decay is 
a major public health problem due to the medical concern that tooth 
decay impairs eating, but also because of the cosmetic effect on societal 
acceptance.129  Overall, the cost to fluoridate water is much less 
 
 126  Id. at 252 (“Recombinant bovine somatotropin was found to increase the risk of 
clinical mastitis by approximately 25% during the treatment period but there was 
insufficient data to draw firm conclusions about the effects of the drug on the 
prevalence of subclinical intra-mammary infections.”). 
 127  Walter L. Hurley, Mastitis Case Studies Mastitis Treatment and Control, 
http://ansci.illinois.edu/static/ansc438/Mastitis/control.html (last visited May 24, 
2016) (“Typically when clinical mastitis is detected, the cow is milked out and then 
given an intramammary infusion of antibiotic, ie. infused directly into the infected 
gland.”).  
 128  Fluoridation Basics, CTR. FOR DISEASE CONTROL, 
http://www.cdc.gov/fluoridation/basics/ (last updated July 28, 2015) [hereinafter 
CDC, Fluoridation Basics]. 
 129  Id.; see also Water Fluoridation, WIKIPEDIA, https://en.wikipedia.org/wiki/Water_ 
fluoridation (last visited May 25, 2016). 
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expensive than the treatment for cavities.130 
The only known adverse effect associated with fluoridated water 
is dental fluorosis, which is a mild condition, usually found on 
children’s teeth that alters the appearance.131  Dental fluorosis is not a 
public health concern and can be tempered by monitoring fluoride 
intake, including toothpaste.132  Over exposure to fluoride is associated 
with minor adverse health effects, which means that fluoridation is 
tightly monitored and adjusted.133  Decades of research demonstrate 
that fluoride levels in the 0.7 milligrams of fluoride per liter of water 
range have the desired public health benefit and have a low risk of 
causing dental fluorosis. 134 
The Center for Disease Control, the American Dental Association 
and the American Medical Association all support fluoridated water 
programs based on the widespread dental health benefits.  Economic 
analysis found that for “every $1 invested in this preventative measure 
yields approximately $38 savings in dental treatment costs.”135 
Not immune from controversy, opponents to fluoridated water 
challenge the science and efficacy.  Some communities in the US are 
moving towards or are enacting non-fluoridation programs.  In 
Portland, Oregon, for example, voters defeated a plan to add fluoride 
to the public water supply.136 
Similar to the above examples, an Internet search reveals a wide 
array of information.  Consumers can find allegations that fluoridation 
is linked to AIDS.137  This does not make sense given that AIDS is caused 
 
 130  CDC, Fluoridation Basics, supra note 128. 
 131  Fluoridation Safety, CTR. FOR DISEASE CONTROL, http://www.cdc.gov/fluoridation 
/safety/index.htm (last updated May 13, 2015) (“Dental fluorosis is a change in the 
appearance of the tooth’s enamel.  These changes can vary from barely noticeable 
white spots in mild forms to staining and pitting in the more severe forms.”). 
 132  FAQs for Dental Fluorosis, CTR. FOR DISEASE CONTROL, http://www.cdc.gov/ 
fluoridation/safety/dental_fluorosis.htm#a9 (last updated Aug. 31, 2015).  
 133  Id. 
 134  Community Water Fluoridation, CTR. FOR DISEASE CONTROL, http://www.cdc.gov/ 
fluoridation/faqs/ (last updated July 28, 2015). 
 135  Cost Savings of Community Water Fluoridation, CTR. FOR DISEASE CONTROL, 
https://www.cdc.gov/fluoridation/factsheets/cost.htm (last updated July 10, 2013). 
 136  Douglas Main, Facts About Fluoridation, LIVESCIENCE (Apr. 30, 2015), 
http://www.livescience.com/37123-fluoridation.html (“For the fourth time since 
1956, voters in Portland defeated a plan in 2012 to add fluoride to the public water 
supply.”). 
 137  See, e.g., Water Fluoridation Controversy, WIKIPEDIA, https://en.wikipedia.org/wiki 
/Water_fluoridation_controversy (last visited May 25, 2016) (“Antifluoridationist 
literature links fluoride exposure to a wide variety of effects, including AIDS, allergy, 
Alzheimer’s disease, arthritis, cancer, and low IQ, along with diseases of the 
gastrointestinal tract, kidney, pineal gland, and thyroid.”). 
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by a virus and fluoride is an element.  Moreover, a person cannot 
contract HIV/AIDS by drinking water.  Action groups against 
fluoridated water programs also exist online.  Fluoride Action 
Network, for example, provides three main reasons to oppose 
fluoridated water programs: (1) outdated mass medication; (2) 
unnecessary and ineffective; and (3) unsafe.138  It is clear from 
reviewing the Fluoride Action Network website that fear is the main 
motivator to influence opposition to fluoridated water.  This website 
strongly suggests that the government is administering drugs to people 
against their will.  Additionally, according to this group, there is no 
benefit to fluoride and the risk of developing disease is high.139 
Given that consumers receive a wide array of information 
regarding the safety and efficacy of fluoridated water programs, it is 
not surprising that consumers may not appropriately assign risk to 
these programs.  If, for example, consumers perceive that there might 
be long-term deleterious consequences from fluoridated water, they 
will inappropriately assign risk to community fluoridation programs.  
Similarly, if consumers perceive the benefit as low, they might assign a 
high risk to these programs.  In addition, consumers may associate 
“goodness” or “badness” with decisions to reject or embrace 
widespread fluoridation programs. 
E. Embryonic Stem Cell Research 
Unlike the above examples, this area of biotechnology raises a 
different issue—that of research funding.  The areas above are already 
in the implementation and application stages.  While some clinical 
trials are in progress, embryonic stem cell research is in a more infant 
stage and will require major sources of funding to capture its full 
potential.  In this controversial area of research, consumers were 
explicitly called on to be part of the conversation and assist in the 
decision as to whether the federal government should fund embryonic 
stem cell research. 
By way of background, in the 1990s, scientists began 
hypothesizing that they could harness the plasticity of embryonic stem 
cells to treat disease.140  Embryonic stem cells are early progenitor cells 
 
 138  Water Fluoridation, FLUORIDE ALERT, http://fluoridealert.org/issues/water/ 
(last visited Oct. 31, 2016).  
 139  See id. 
 140  Stem Cell Information: Stem Cell Basics, NAT’L INSTS. OF HEALTH, 
https://stemcells.nih.gov/info/basics/1.htm (last visited Dec. 31, 2016) [hereinafter 
NIH STEM CELL INFORMATION]. 
SAX (DO NOT DELETE) 2/16/2017  2:44 PM 
460 SETON HALL LAW REVIEW [Vol. 47:433 
that have the ability to turn into many different cell types.141  Cell 
signals are given to these early progenitor cells to tell them to become 
muscle, organ, neural or skeletal cells.142  Since many human ailments 
are characterized by a loss of function of particular cells, the idea was 
that the diseased cells could be replaced by non-diseased cells.143  Put 
differently, if an individual’s pancreas, for example, has problems with 
insulin producing cells, the patient could be treated with a stem cell 
therapy to replace the diseased pancreatic cells with healthy pancreatic 
cells.  This similar, hypothetical approach could be used to treat major 
ailments such as Parkinson’s disease, Alzheimer’s Disease, muscular 
dystrophy, and others.144 
Controversy ensued regarding the starting material for embryonic 
stem cell research, which is fertilized eggs—created in vitro.145  
Opponents to embryonic stem cell research claimed that the fertilized 
eggs had the potential for human life, thus this type of research was 
unethical.146  Proponents of embryonic stem cell research looked at the 
fertilized eggs as cells and also promoted the potential to treat 
disease.147  Some consumers may sit in the middle of this debate—that 
is, they may not personally have a moral objection, but they may be 
sympathetic to others who do.  Thus, while a large part of the debate 
has value-based or religious undertones, some portion of the debate is 
likely more nuanced than any particular value-based belief. 
The debate about whether the federal government should fund 
embryonic stem cell research came to a head in 2001 under President 
George W. Bush.148  To address this topic, President Bush relied heavily 
on the Presidential Commission for Bioethics.149  This panel advises the 
President on bioethical issues.150  Leon Kass, the Chair of the 
Commission, took center stage during this debate for his views against 
 
 141  Id. 
 142  Id. 
 143  Joanna K. Sax, The States “Race” with the Federal Government, 15 ANNALS OF HEALTH 
L. 1, 8 (2006) [hereinafter Sax, The States “Race” with the Federal Government]. 
 144  Id. 
 145  Id. at 9 (citing Allen M. Spiegel & Gerald D. Fischbach, NIH Statement Before 
Senate Appropriations Subcommittee, NAT’L INSTS. OF HEALTH (Apr. 26, 2000), 
https://stemcells.nih.gov/policy/statements/State.htm). 
 146  Joanna K. Sax, The Separation of Politics and Science, 7 STAN. J.L. SCI. & POL’Y 10, 
16 (2014) [hereinafter Sax, The Separation of Politics and Science].  
 147  Id.  
 148  Sax, The States “Race” with the Federal Government, supra note 143, at 15. 
 149  Id. at 16. 
 150  About the Commission, PRESIDENTIAL COMMISSION FOR THE STUDY OF BIOETHICAL 
ISSUES, http://bioethics.gov/about (last visited May 25, 2016).  
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the funding of embryonic stem cell research.151  Elizabeth Blackburn, 
who was not reappointed to the Presidential Commission for Bioethics 
during this time, charged the administration with stacking the 
Commission with members who aligned with Leon Kass.152  It was a 
political debate. 
During this time, the issue of whether to provide federal funding 
to research embryonic stem cells was heavily publicized and divisive, 
with a lot of press in both mainstream newspapers as well as in scientific 
journals.153  In many ways, the issue was raised as a moral issue to which 
some politicians wanted constituent feedback.  As a representative 
democracy, this should seem copasetic with our political process. 
Given the highly publicized and politicized nature of the issue of 
federal funding for embryonic stem cell research, one study analyzed 
the type of information provided to the public regarding embryonic 
stem cell research.154  A major contention during this time was whether 
scientists could use adult stem cells to achieve the same results as 
embryonic stem cells and thus avoid needing to use the controversial 
starting material.155  Scientists contended that they could not make this 
determination unless and until experiments on both adult and 
embryonic stem cells were conducted.156  Some articles in mainstream 
newspapers, however, reported that adult stem cells might provide 
equivalent starting material as embryonic stem cells.157  This reporting 
occurred at different frequencies in different newspapers, but 
nevertheless, the information was conveyed to the public. 
The reporting of different information, either that adult stem 
cells are not equal to embryonic stem cells, or that adult stem cells 
might be equal to embryonic stem cells, creates ambiguity.  How is a 
typical consumer going to weigh that information?  Those with a moral 
opposition to embryonic stem cell research might perceive the 
information differently than those without a moral opposition.  That 
is, a person may not be personally opposed to the research, but s/he 
may be sympathetic to those who are.  If people perceive that a 
workable compromise exists, i.e., only performing research on adult 
stem cells since they are likely to provide the same information, then 
they will make a decision accordingly.  Put differently, even those 
 
 151  Sax, The States “Race” with the Federal Government, supra note 143, at 17. 
 152  Id. 
 153  See, e.g., Sax, The Separation of Politics and Science, supra note 146, at 8–10. 
 154  Id. at 7–14. 
 155  Id. at 8–9. 
 156  Id. at 9. 
 157  Id. at 12. 
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without a moral opposition to embryonic stem cell research might be 
impartial to a decision not to fund embryonic stem cell research given 
information that a different starting material might give the same 
results. 
Similarly, affect can impact how consumers view funding of 
controversial research.  Consumers, for example, might experience 
“badness” at the thought of funding embryonic stem cell research.  
Whereas other consumers might experience “goodness” at the thought 
of the decision to support research that has the potential to treat 
debilitating disease(s). 
In 2001, President Bush signed an executive order that placed a 
practical ban on the funding of embryonic stem cell research.158  In 
2009, with a leadership change, President Obama changed course and 
allowed federal funding for the creation and experimentation on new 
stem cell lines.159 
As articulated elsewhere, changes in funding that appear to be 
dependent on the administration in charge creates major issues for 
scientific inquiry and innovation.160  Putting aside the issues with 
funding, this example has similarities with the other biotechnology 
examples discussed above.  Here, the consumers are asked to make 
decisions when there may be incomplete, or even incorrect, 
information provided—thus incorporating ambiguity.  On top of that, 
controversial research may incorporate feelings of goodness or 
badness with a decision. 
By way of more explicit analogy, the discussion regarding 
vaccinations (supra Part II.A) has many similarities to the issues with 
funding embryonic stem cell research.  First, consumers can search for 
and obtain a wide amount of information about either issue on the 
Internet.  For example, an Internet search might provide mis-
information that vaccines cause autism and embryonic stem cell 
research is the same thing as an abortion.161  Conversely, an Internet 
 
 158  Sax, The States “Race” with the Federal Government, supra note 143, at 15. 
 159  Removing Barriers to Responsible Scientific Research Involving Human Stem 
Cells, 74 Fed. Reg. 10,667 (Mar. 11, 2009). 
 160  Sax, The Separation of Politics and Science, supra note 146, at 11–14.  
 161 Arjun Walia, 22 Medical Studies that Show Vaccines Can Cause Autism, ACTIVIST POST 
(Sept. 12, 2013), http://www.activistpost.com/2013/09/22-medical-studies-that-show-
vaccines.html; Stem Cell Research, SOC’Y FOR THE PROTECTION OF UNBORN CHILD., 
https://www.spuc.org.uk/abortion/embryo-abuse/stem-cell-research (last visited May 
24, 2016).  But see Vaccines Do Not Cause Autism, CTR. FOR DISEASE CONTROL, 
http://www.cdc.gov/vaccinesafety/concerns/autism.html (last updated Nov. 23, 
2015); Myths and Misconceptions about Stem Cell Research, CAL. INST. FOR REGENERATIVE 
MED., https://www.cirm.ca.gov/patients/myths-and-misconceptions-about-stem-cell-
research (last visited May 24, 2016) (“Embryonic stem cells only come from four 
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search might provide information that vaccines save lives and that 
embryonic stem cell research will be a key to treating individuals with 
Alzheimer’s Disease.162  Consumers in both of these situations will be 
evaluating inconsistent and even contradictory information, which 
makes it difficult to assign risk to a particular outcome.  Similarly, given 
the emotionally laden undertone of these controversial areas, 
consumers may experience “goodness” or “badness” with any 
particular decision. 
Widespread applications of biotechnology do not have the ability 
to satiate all individual concerns and preferences.  In other words, 
fluoridated water programs cannot indicate which homes would 
support the programs versus those which would not, because the 
public water supply is supplied to each home.  Vaccination programs 
require requisite levels of herd immunity to be effective.  Embryonic 
stem cell research is either funded or not.  The issue then becomes: 
how do policymakers not only separate the wheat from the chaff, but 
also provide information to consumers so that they can appropriately 
assign risk to new applications of biotechnology?  This article turns to 
this issue in Part III. 
III.  CONSUMER DECISION-MAKING AND POLICY 
Understanding consumer decision-making is important when 
drafting and implementing policies.  Research in decision-making 
informs us that consumers may not appropriately assign risk to an 
outcome when there are unknowns.  In addition, consumers tend to 
be more sensitive to information about possible risks than to 
information about potential benefits.163  Studies show that consumers 
are skeptical of information provided by pharmaceutical companies 
(vaccines, rbST, and fluoridated water), agriculture companies 
(GMOs), and often even scientists (embryonic stem cell research).164  
 
to five day old blastocysts or younger embryos.”).  
 162 See, e.g., Stem Cell Research, ALZHEIMER’S SOC’Y, https://www.alzheimers.org.uk/ 
site/scripts/documents_info.php?documentID=1039 (last updated August 2012). 
 163  Montserrat Costa-Font & Jose M. Gil, Does Expert Trust and Factual Knowledge 
Shape Individual’s Perception of Science?, 36 INT’L J. CONSUMER STUD. 668, 670 (2012). 
 164  See, e.g., Mark Kessel, Restoring the Pharmaceutical Industry’s Reputation, 32 NATURE 
BIOTECHNOLOGY 983, 983 (2014); Maria Altman, Monsanto Appeals Directly to Consumers 
in New Ad Campaign, ST. LOUIS PUBLIC RADIO (Nov. 5, 2014), 
http://news.stlpublicradio.org/post/monsanto-appeals-directly-consumers-new-ad-
campaign; Michael McNichol & Zubin Master, Ethical and Scientific Issues Towards the 
Successful Translation of Stem Cell Research, BIOETHICS TODAY (Jan. 27, 2014), 
http://www.amc.edu/BioethicsBlog/post.cfm/ethical-and-scientific-issues-towards-
the-successful-translation-of-stem-cell-research (“Several social science studies have 
shown that patients and the general public trust research done in the public sphere 
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On top of this, information regarding technology is imperfect due to 
degrees of scientific uncertainty.165  Utilizing communication tactics to 
explain the unknowns or to allow information to be less ambiguous 
may assist consumers in assigning risk to a particular decision. 
Recent scholarship in this area suggests that providing 
information to consumers in a manner consistent with decision-
making theories may assist consumers in assigning risk.166  In a recent 
study, Costa-Font and Gil made a number of interesting observations.167  
Understanding the science, for example, was associated with a lower 
perception of risk.  Conversely, a lack of understanding of the 
underlying science was associated with higher perceptions of risk.168  
This supports the idea that consumers perceive risks as high when 
there is either not enough information or the information is 
ambiguous.169  Perhaps not surprisingly, Costa-Font and Gil also found 
that trust in the expert conveying the information was important to 
consumers.170 
It might seem easy enough to say that trusted experts should 
provide the scientific information and that this will lead consumers to 
be in a better position to assign risk.  Scientists, however, are not 
classically trained to translate their discoveries to the general public.171  
The problem with this approach is that not only is it not working but 
there are forces that actively oppose it.  Marketing professionals, for 
example, frequently exploit the nuances of consumer decision-
making.172  The organic food industry, for example, may actively use 
 
(e.g., publically funded universities and colleges), and are less trustworthy of research 
performed in private and commercial institutions e.g., pharmaceutical or biotech 
industry.  While these same studies also indicate that the public is more than willing to 
participate in stem cell research by donating tissues, some still don’t like the idea of a 
company making profit and the volunteers not seeing any direct benefit from their 
participation in research.”). 
 165  Costa-Font & Gil, supra note 163, at 670. 
 166  Id. at 673. 
 167  Id. 
 168  Id. 
 169  Id. 
 170  Id. at 675. 
 171  See Center for Public Engagement with Science & Technology, AM. ASS’N FOR THE 
ADVANCEMENT OF SCI., http://www.aaas.org/pes/communicatingscience (last updated 
Nov. 3, 2016) [hereinafter AAAS].  
 172  See Slovic, What’s Fear Got to Do with It?, supra note 36, at 983 (“There are two 
important ways that experiential thinking misguides us.  One results from the 
deliberate manipulation of our affective reactions by those who wish to control our 
behaviors.  (Advertising and marketing exemplify this manipulation).  The other 
results from the natural limitations of the experiential system and the existence of 
stimuli in our environment that are simply not amenable to valid affective 
representation.”). 
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affect and ambiguity to scare consumers away from food produced 
from GMOs.  Put differently, the organic food industry has an 
economic interest to entice consumers to buy organic food and not to 
buy food from GMOs.  By making consumers feel “goodness” about 
organic food and “badness” about food from GMOs, the organic 
industry can exploit consumer decision-making. 
A recent study by Hughner and colleagues analyzed which types 
of individuals are organic food consumers.173  In surveying several 
studies, they identified certain demographics that stand out: organic 
food consumers tend to be female, have children, and are older, 
though these characteristics are not mutually exclusive of each other.174  
Research also suggested that organic food consumers see their 
preference associated with a “way of life” and with an ideology.175  
Hughner and colleagues articulated nine themes associated with 
consumer motivations and six themes associated with consumer 
deterrents when deciding whether to purchase organic food.176  The 
motivations included: (1) healthier; (2) tastes better; (3) 
environmental concern; (4) concern over food safety; (5) concern 
over animal welfare; (6) supports local economy and sustain 
traditional cooking; and (7-9) wholesome, reminiscent of the past, and 
fashionable.177  Deterrents included: (1) high prices; (2) lack of 
availability; (3) skepticism of certification boards and labels; (4) 
insufficient marketing; (5) satisfaction with current food source; and 
(6) cosmetic defects.178 
A recent study showed that survey participants perceive that 
organic farmers care more about health, safety, and environmental 
friendliness compared to conventional or GMO farmers.179  Likewise, 
participants also perceive that farmers who grow GMO crops care more 
about efficiency (and less about health, safety, and the environment) 
compared to organic farmers.180  This perception is unlikely to be 
resolved by statements or advertisements by Monsanto (a major 
supplier of genetically engineered seeds), especially given consumer 
mistrust of some big corporations.181  Interestingly, it may be that large-
scale industrial farms are more environmentally friendly given that 
 
 173  Hughner et al., supra note 72, at 94.  
 174  Id. at 96. 
 175  Id. 
 176  Id. at 101–04. 
 177  Id. at 101–03. 
 178  Id. at 103–04. 
 179  Sax & Doran, supra note 22. 
 180  Id. 
 181  See Altman, supra note 164. 
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they have the capacity to invest in technology that tends to be more 
“gentl[e] on the environment.”182 
The information containing the scientific consensus about the 
various technologies discussed in this article is available for the public 
to read.  The Center for Disease Control, for example, provides 
information about the safety and efficacy of vaccines.183  It is not just 
that the information be provided in order for the consumer to make a 
decision—that is not sufficient.  This is because a consumer can 
perform an Internet search on “vaccines and autism” and locate 
information, albeit incorrect, about a link between the two.  Thus, 
consumers receive contradictory and ambiguous information, and 
they don’t know how to appropriately wade through all of it.184  In this 
example, if a parent believes that his/her child might become autistic 
due to vaccinations, s/he will feel “badness” in making a decision to 
vaccinate.  Therefore, the method of communication must take into 
account affect and ambiguity, especially as we are in the information 
age. 
Even major scientific reports are unlikely to resolve the mass 
amount of contradictory information provided to consumers.  In May 
2016, the National Academies of Science released a comprehensive 
report about the health, safety and environmental friendliness of 
genetically engineered food.185  Through a painstaking review of the 
relevant literature, the National Academies of Science concluded the 
following: 
(1) Effect on Environment: “Overall, the committee found 
no evidence of cause-and-effect relationships between GE 
crops and environmental problems.”186 
(2) Human Health: “[T]he research that has been 
 
 182  Jayson Lusk, Why Industrial Farms are Good for the Environment, N.Y. TIMES, Sept. 
25, 2016, at SR4, http://www.nytimes.com/2016/09/25/opinion/sunday/why-
industrial-farms-are-good-for-the-environment.html?_r=0. 
 183  CDC, Vaccine Safety, supra note 48. 
 184 But see George Johnson, The Widening World of Hand-Picked Truths, N.Y. TIMES 
(Aug. 24, 2015), http://www.nytimes.com/2015/08/25/science/the-widening-world-
of-hand-picked-truths.html?_r=0 (“Google recently tweaked its algorithm so that 
searching for ‘vaccination’ or ‘fluoridation,’ for example, brings vetted medical 
information to the top of the results.”).  
 185  National Academy of Sciences, Genetically Engineered Crops: Experiences and 
Prospects, THE NAT’L ACADEMIES PRESS (May 17, 2016), http://www.nap.edu/catalog/23 
395/genetically-engineered-crops-experiences-and-prospects [hereinafter N.A.S., 
Genetically Engineered Crops]; see also Henry I. Miller, National Academy of Sciences ‘GMO’ 
Report Does Science no Favors, FORBES (May 24, 2016, 5:00 AM), 
http://www.forbes.com/sites/henrymiller/2016/05/24/national-academy-of-
sciences-gmo-data-dump-leaves-over-regulation-intact/#151a8d347a0b. 
 186  N.A.S., Genetically Engineered Crops, supra note 185, at 100.  
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conducted in studies with animals and on chemical 
composition of GE food reveals no differences that would 
implicate a higher risk to human health from eating GE 
foods than from eating their non-GE counterparts.”187 
(3) Social and Economic Effects: “[E]xisting GE crops have 
generally been useful to large scale farmers of cotton, 
soybean, maize and canola.  The same GE crops have 
benefitted a number of small-scale farmers, but benefits have 
varied widely across time and space, and are connected to the 
institutional context in which the crops have been 
deployed.”188 
The National Academies Report essentially regurgitated much of 
what scientists have known for a long time, but was equivocal at times, 
citing the need for additional studies.189  Since the scientific process 
necessarily leads to additional questions, some familiar in this field 
have suggested that the calls for additional studies can be taken out of 
context.190  Put differently, just because additional studies are needed 
does not mean that we do not know enough to implement sensible 
policies and regulations. 
The issue is not only how to communicate the science of the 
technology so that consumers have the factual information to 
appropriately assign risk, but also how to combat false, ambiguous, or 
misleading information.  Since ambiguous information is available on 
the Internet, it is not possible to provide only accurate information to 
consumers.  Instead, different platforms must be created to provide 
correct information in a way that considers how consumers make 
decisions. 
Dread is an important feeling involved with risk perception.191  
Recent studies demonstrate that “perceptions of risk and society’s 
responses to risk were strongly linked to the degree to which a hazard 
evoked feelings of dread.  Thus, activities associated with cancer are 
seen as riskier and more in need of regulation than activities associated 
with less dreaded forms of illness, injury, and death (e.g., accidents).”192  
Other studies analyzing the role of affect in decision-making show an 
inverse relationship: “judgments of risk and benefit are negatively 
 
 187  Id. at 156. 
 188  Id. at 221; see also Strauss & Sax, supra note 82, at 476 (discussing how the time 
and cost of the regulatory process impedes small farmers from taking advantage of the 
technology). 
 189  Miller, supra note 185. 
 190  Id. 
 191  Slovic, The Affect Heuristic, supra note 14, at 1342 (internal citation omitted).  
 192  Id. 
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correlated.”193  Results from studies showing this inverse relationship 
suggest that “people base their judgments of an activity or a technology 
not only on what they think about it but also what they feel about it.  If 
they like an activity, they are moved to judge the risks as low and the 
benefits as high; if they dislike it, they tend to judge the opposite: high 
risk and low benefit.”194 
Another potential problem for policies that implement 
technology is the recognition that scientific theories and paradigms 
change over time.  Science is about asking questions and testing 
hypotheses.  This process leads to major paradigm upheavals (compare 
Newton to Einstein) and even smaller paradigm shifts (eating high-fat 
food is not as bad as was once thought).  To be fair, even if the correct 
information is provided to consumers in a way that allows them to 
assign risk, the application of scientific discovery will (and should) face 
some healthy skepticism, especially given the incremental changes and 
paradigm shifts.  However, overall we live longer and healthier lives 
compared to previous generations.  So, the fear of the potential 
unknowns in science should be evaluated within this larger context. 
So, where do we go from here?  This article proposes several 
approaches for policymakers to consider, all of which use decision-
making theories to assuage consumer concerns, allow consumers to 
appropriately assign risk, and to make informed decisions.  These 
suggestions promote studying the influence and role of affect and 
ambiguity as a component to drafting, adopting, and implementing 
policy.  Affect and ambiguity have not played a major role in the legal 
policy arena.195  The studies described in Part II support the hypothesis 
that affect and ambiguity are playing a role in how consumers are 
responding to policies that implement biotechnology.  Given that the 
examples described in Part II—vaccines, GMOs, rbST, fluoridated 
water, and embryonic stem cell research—are not controversial within 
the scientific community, it is important to understand why consumers 
perceive risks so differently than the experts.  With large-scale 
problems, such as climate change and health care, needing to be 
 
 193  Id. 
 194  Id. at 1343. 
 195  See Peters et al., supra note 36, at 79 (citation omitted) (“The field of judgment 
and decision making (JDM) long neglected the influence of ‘hot processes’ on 
decision behavior in favor of a focus on ‘cold,’ deliberative, and reason-based decision 
making.  Historically, this was due at least in part to hot processes being viewed 
primarily as biased, leading to irrational choice behavior.  However, over the last ten 
years the JDM field has turned its attention more and more to how affective feelings 
influence judgments and decisions.  Today, emotion and affect are on the research 
agenda for many JDM researchers.”). 
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addressed, consumers’ perceptions of risk must come closer to the 
actual risks as evaluated by experts.  Otherwise, this tension will likely 
increase and lead to the same type of rejection that has occurred with 
nuclear energy.196 
Based on the information described above, this article articulates 
four themes that consider both what we already know and where we 
should consider going.  All four of these themes posit that affect and 
ambiguity play important roles in obtaining consumer support for 
policy implementation.  Within each theme, this article describes 
examples of possible future directions for studies by using vaccines, 
GMOs, rbST, fluoridated water, and embryonic stem cell research as 
test cases.  This article briefly proposes examples of pilot studies that 
can be conducted.  While the general outline of ways to examine the 
themes are discussed below, detailed studies that utilize software suites 
dedicated to behavioral studies, large-scale consumer analyses and 
other approaches could form the basis for grant applications and 
potentially funded studies.  The below discussion is meant to open a 
dialogue and conversation for future directions and collaborations. 
Some of the themes below have overlapping concerns for policy 
implementation.  An example of an overlapping concern is how to 
address consumer autonomy in public health policy implementation, 
such as vaccinations and fluoride in the water supply.  On the other 
hand, each area of technology poses individual or unique concerns.  
While recombinant DNA technology forms the underlying 
technological basis for both rbST and GMOs, these areas of 
biotechnology face independent challenges in policy implementation.  
To address the overlapping and individual issues, each example is 
discussed within each of the themes.  To highlight the differences, this 
article suggests ways to conduct studies to test whether and how each 
theme might apply to each example.  The purpose of this is to stress 
that: (1) a one-approach-fits-all will not work for implementation of 
controversial areas of technology; and (2) future studies catered 
towards each example that test the role of affect and ambiguity can be 
conducted.  The next few subsections are forward-thinking in that the 





 196  See Walsh, supra note 11. 
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A. Theme 1: Separate the Wheat from the Chaff: Allow Consumers to 
make Informed Choices 
First, informed decisions should be based on accurate 
information.197  This problem is starkly seen in the vaccination wars.  
VHPs resist vaccination based on concerns of linkage to autism, 
irreversible harm, low likelihood of contracting the actual disease, and 
perhaps an incorrect understanding of the devastating impact of the 
vaccine-preventable disease.198  These beliefs are based on inaccurate 
information; thus, the consumers are not making informed decisions.  
While individual autonomy regarding the decision to vaccinate or not 
presents major public health challenges, due to the requirement for 
herd immunity, it may be possible to soften the resistance to 
vaccinations simply by providing consumers with accurate 
information.  Studies should be aimed at testing how to provide 
accurate information to consumers in a way that allows them to 
appropriately assign risk.  An example of a specific study could test 
whether environmental differences impact how consumers receive and 
process information.  For example, would  a mobile-nurse (or other 
health care professional) visiting a family in their home to both 
provide information and answer questions have an impact on decision-
making, as compared to no home visit?  Or, perhaps, could literature 
about vaccines be provided via U.S. Mail prior to a doctor’s visit to assist 
with providing accurate information to consumers?  These prior visits 
or mailings could be presented with a “happy” inference such that 
consumers may experience some sort of positive feeling associated with 
the information.  This could be compared to simply providing 
information at a doctor’s visit.  This type of study incorporates both 
affect and ambiguity in analyzing how consumers respond to the 
presentation of accurate information. 
In the debate surrounding GMOs, food labeling laws provide a 
helpful example in which consumers seek to make informed decisions.  
If consumers want to know information about their food, including the 
source, then food labeling laws can respond to consumer needs.  
During the past several years, at least thirty-five states have introduced 
food labeling laws related to genetically engineered food.199  These laws 
 
 197  See Slovic, What’s Fear Got to Do with It?, supra note 36, at 989 (“It seems obvious 
that designers of risk education and communication programs should work with 
experts in these fields, yet this does not seem to be happening.  Such collaboration 
would help the government to work with the intended audience of each message.  
Designers need to listen to the public’s concerns, collaborate in message development, 
and test messages and programs to see if they are working as intended.”). 
 198  Blaisdell et al., supra note 19, at 483–85. 
 199  Sax & Doran, supra note 22. 
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can certainly be neutral and allow consumers to have information.  
The problem is that consumers make inappropriate associations with 
various food labels.200  In one study, survey participants found the GMO 
label to be less healthy, less safe, and less environmentally friendly 
compared to a variety of other labels, including the labels “organic” 
and “natural.”201  Since the label “natural” has no regulatory definition, 
such a label does not provide information to consumers.202  But, 
marketing companies know that consumers have positive associations 
with the term “natural” and this is seen very prominently in the dietary 
supplement industry.203  A recent episode of Keeping Up With the 
Kardashians showed Kourtney Kardashian food shopping with her son.  
In this episode, Ms. Kardashian found gum labeled “natural” and 
seemed very pleased to offer this gum to her son.  It would be 
interesting to know if the ingredients in the gum labeled “natural” 
differ compared to other commercial gum.  Labels appear to matter to 
consumers, which is completely fine, but the labels should provide 
information in a way that allows consumers to make informed choices.  
If consumers want to know that their food is healthy, for example, then 
labels can respond to that concern.  The problem is that the label 
“natural,” for example, does not accurately provide that information, 
but many consumers think that it does.204 
In the GMO controversy, understanding consumer preferences 
can allow policymakers to provide accurate information in a way that 
responds to the consumer needs.  For example, studies could divide 
subjects into different groups and provide accurate information in a 
way that responds to consumer preferences.  Testing participant 
responses via survey could be used to analyze whether the information 
provided led to different responses.  Put differently, policymakers need 
to understand how to communicate with consumers so that the 
 
 200  Id. 
 201  Id. 
 202  “Natural” on Food Labeling, FOOD & DRUG ADMIN., 
http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInf
ormation/LabelingNutrition/ucm456090.htm (last updated May 9, 2016) 
(responding to citizens petitions to try to establish a definition for the term “natural”). 
 203  See Joanna K. Sax, Dietary Supplements are Not all Safe and Not all Food: How the Low 
Cost of Dietary Supplements Preys on the Consumer, 41 AM. J.L. & MED. 374, 377 (2015) 
(internal citations omitted) (“Manufacturers exploit this preference in their 
marketing techniques, by touting their supplement as ‘natural.’  The perception of 
some consumers is that anything that is natural is safe.  But, of course, that is not true.  
Many poisonous and dangerous things are natural, such as wild mushrooms.  Tobacco 
is another natural ingredient that is linked to adverse health consequences.”). 
 204  See, e.g., Andrew Sullivan, Naturally Nonsense, THE DISH (June 25, 2014, 5:17 PM), 
http://dish.andrewsullivan.com/2014/06/25/naturally-nonsense/. 
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consumers can separate the wheat from the chaff.  A specific study 
could include statements by smaller farmers who want to use 
biotechnology to address a niche problem in their area.  Studies show 
that consumers perceive organic farming as local and small, and like 
the idea of a return to wholesomeness.205  Consumers may be surprised 
to learn biotechnology can be used to solve niche problems, but that 
it has been kept out of reach of small, local farmers due to the time 
and expense associated with regulatory review.206  For consumers who 
are concerned about sustainable farming, for example, they may be 
interested to learn that the use of genetic engineering to solve a 
distinct problem, such as a virus that infects crops in a particular area 
of the country, is out of reach for some farmers, leading to crop loss.  
Additional information about health and safety profiles of genetically 
engineered food may also be illustrative to consumers.  By 
understanding the preferences of consumers, information can be 
provided in a way that accurately responds to these concerns.  Perhaps 
small farmers who want to use genetically engineered crops can reach 
the consumers who are attracted to the same attributes that they 
associate with local organic farming.207  Put differently, some of the 
reasons that consumers chose to buy organic are also reasons to buy 
food made from local farmers who want to use biotechnology to solve 
a niche problem.  Consumers may be unaware of the benefits of food 
produced from GMOs.  If consumers understand the application of 
biotechnology, they may see the benefit as high and possibly assign a 
lower probability of risk. 
The controversy surrounding the treatment of dairy cows with 
rbST overlaps with the GMO debates.  To date, no scientific consensus 
exists that treatment of cows with rbST causes health issues in humans.  
But, consumers who see an “rbST-free” label might relate this label 
with some sort of negative association, such as a health or safety issue; 
i.e. with milk from cows treated with rbST.  Empirical studies analyzing 
consumer associations with rbST labels can easily be conducted, in a 
similar fashion as the GMO labeling study described above.  Additional 
studies can be aimed at providing accurate information regarding 
 
 205  Hughner et al., supra note 72, at 101–03.  See also, for example, a pro-organic 
company called WHOLESOME!, http://wholesomesweet.com/ (last visited Nov. 23, 
2016). 
 206  See Strauss & Sax, supra note 82, at 475 (internal citation omitted) (“This is a 
major factor preventing most small companies and public sector breeders from using 
GMO methods. . . .  This recognizes that the current regulations have the practical 
consequence of keeping innovations out of the marketplace, including more 
environmentally friendly or healthy alternatives.”).  
 207  Control groups would also be included in any study. 
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rbST treated cows in an attempt to see if this changes consumer 
responses to various labels. 
Fluoridated water programs are similar to vaccination programs 
because of the widespread implementation.  Adding fluoride to the 
public water supply makes it very difficult for a consumer to opt out.  
In addition, the risk of any adverse event from fluoride in the water is 
very low and the public health benefit is very high.208  For this reason, 
it is important to compare whether different methods of 
communication that provide accurate information change the way 
consumers make decisions.  Whether consumers respond differently 
can be tested using focus groups or responses to survey questions. 
In the debate surrounding embryonic stem cell research, 
consumers received conflicting and inaccurate information.  As 
discussed earlier, one study showed that mainstream newspapers 
inaccurately reported that adult stem cells were equal to embryonic 
stem cells, suggesting that research on embryonic stem cells was not 
needed.209  It is unclear if consumers were used as pawns in a political 
debate, but that is certainly an inference that can be made.  In the past 
fifteen years, scientists have learned much more about stem cells in 
general.  In some cases, adult stem cells do provide a better starting 
material compared to embryonic stem cells and vice versa.210  This is 
important information obtained through many years of research.211  
Scientists do not know the answers until they test their hypotheses.  
Consumers should be provided with information based on actual data 
in order to make informed decisions about controversial areas of 
funding.  A longitudinal study analyzing consumer perceptions of 
embryonic stem cell research over time might provide interesting 
information to see if perceptions change as more information is 
obtained. 
When consumers do not understand the science, they are more 
likely to inappropriately assign a high risk to that particular application 
 
 208  See generally supra Section II.D. 
 209  Sax, The Separation of Politics and Science, supra note 146, at 17. 
 210  Stem Cell Basics – What are the similarities and differences between embryonic and adult 
stem cells?, NAT’L INSTS. OF HEALTH, http://stemcells.nih.gov/info/basics/pages/basics 
5.aspx (last updated Mar. 3, 2015) (“Scientists believe that tissues derived from 
embryonic and adult stem cells may differ in the likelihood of being rejected after 
transplantation. . . . Adult stem cells, and tissues derived from them, are currently 
believed less likely to initiate rejection after transplantation.”). 
 211  See, e.g., Stem Cell Basics – What are adult stem cells?, NAT’L INSTS. OF HEALTH, 
http://stemcells.nih.gov/info/basics/pages/basics4.aspx (last updated June 17, 
2015) (“In a variation of transdifferentiation experiments, scientists have recently 
demonstrated that certain adult cell types can be ‘reprogrammed’ into other cell types 
in vivo using a well-controlled process of genetic modification[.]”).  
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of technology.  Consumers should be in a position to make informed 
decisions.  The concern is that with so much conflicting information 
available, it is challenging for a consumer to know what information to 
use.  Studies are needed to understand the best ways to provide 
accurate information to consumers to allow them to be in a position to 
appropriately assign the benefits and risks to a particular decision.212 
B.  Theme 2: Scientific Uncertainty is Different than Risk 
Second, scientific uncertainty is part of the scientific process.  
Unknowns always exist in science, but this is different than having 
enough information to be able to assign a probability of risk.  
Consumers may have trouble differentiating between scientific 
uncertainty and risk.  The question becomes how to communicate not 
only the science, but also that some scientific uncertainty still allows 
consumers to assign a risk.  The American Association for the 
Advancement of Science (AAAS) has dedicated significant efforts to 
creating interactions between scientists and society.213  Corporations 
and other interested actors are also testing and implementing 
consumer outreach programs.214  Scientific uncertainty does not mean 
that policymakers do not have enough information to make informed 
policy decisions. 
A physician may never be able to say that vaccines are 100 percent 
safe all the time and that no adverse event could ever be related to a 
vaccine.  Some small risks exist.  A small risk of infection, for example, 
might occur at the injection site.  This uncertainty however, pales in 
comparison to the overwhelming amount of evidence regarding the 
benefits of vaccines.  An example of scientific uncertainty might be 
testing and revisiting the best timing for administration of 
immunization to allow patients to obtain the highest level of immunity.  
This type of scientific uncertainty and need for ongoing studies should 
not be confused with the overwhelming amount of evidence 
demonstrating the efficacy of vaccines.  Consumers may conflate risk 
and uncertainty in the following way: a parent might believe that 
because recommended doses and timing of those doses change, the 
scientific community does not really understand what it is doing, and 
 
 212  The author is grateful to a colleague who used the terminology, separating 
wheat from chaff, to describe an issue (although in another setting).  This description 
spurred the name for this theme. 
 213  See AAAS, supra note 171. 
 214  See, e.g., The Conversation, MONSANTO, http://discover.monsanto.com/ 
conversation/ (last visited May 24, 2016) (providing a forum for consumers to ask 
questions). 
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therefore assign a high risk to any vaccination protocol or 
recommendation.  To be fair, the skepticism of scientific uncertainty 
may be greater in consumers due either to changes in medical advice 
(for example, fat is not as bad as we once thought for our diets) or 
larger paradigm shifts.  But, as discussed earlier in this article, this must 
be fairly balanced with overwhelming evidence that scientific advances 
allow us to live longer and healthier lives compared to our ancestors. 
The studies described within this article can provide important 
insight regarding how consumers make decisions when the risks are 
unknown.  If consumers experience the feeling of dread, they are likely 
to assign a high risk to the outcome.215  If consumers feel that the 
administration of a vaccine to their children will cause major long-term 
and irreversible problems, they may choose not to vaccinate.216  
Perhaps because scientists and physicians may never be able to say that 
vaccines are 100 percent safe, parents may experience a negative affect 
if they think that their children would be part of the very small group 
that has an adverse reaction.  Would consumers feel differently about 
the assignment of risk of a vaccine if it is placed in the context of other 
types of risks?  The risk of being killed in a driving accident is greater 
than the risk of an adverse event from a vaccine.217  Studies can test 
whether the negative feelings associated with particular decisions can 
be adjusted by providing information about risk.  Would consumers 
feel differently about the assignment of risk if they understood the 
difference between scientific uncertainty and risk?  Studies are needed 
to evaluate how to provide this type of information to consumers in 
such a way. 
The scientific consensus for food produced from GMOs is that it 
is as safe as conventional food.218  It is possible that in the future some 
 
 215  Slovic, The Affect Heuristic, supra note 14, at 1342.  
 216  Cf. Blaisdell et al., supra note 19, at 483–85. 
 217  Compare General Statistics, INS. INST. FOR HIGHWAY SAFETY, 
http://www.iihs.org/iihs/topics/t/general-statistics/fatalityfacts/state-by-state-
overview (last visited June 11, 2016) (“There were 29,989 fatal motor vehicle crashes 
in the United States in 2014 in which 32,675 deaths occurred.”), with Aaron 
Sharockman, What CDC Statistics Say about Vaccine-Related Illnesses, Injuries and Death, 
POLITIFACT (Feb. 3, 2015, 3:32 PM), http://www.politifact.com/punditfact/statements 
/2015/feb/03/bob-sears/what-cdc-statistics-say-about-vaccine-illnesses-in/ (reporting 
data on vaccine related deaths at 122 for the year 2014, with the VEARS disclaimer that 
“[w]hen evaluating data from VAERS, it is important to note that for any reported 
event, no cause-and-effect relationship has been established.  Reports of all possible 
associations between vaccines and adverse events (possible side effects) are filed in 
VAERS.  Therefore, VAERS collects data on any adverse event following vaccination, 
be it coincidental or truly caused by a vaccine.  The report of an adverse event to 
VAERS is not documentation that a vaccine caused the event”). 
 218  See Press Release, supra note 93. 
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type of conventional food or food produced from a GMO might not 
be safe.  This possibility is a scientific uncertainty, but should not be 
used for risk assignment by consumers.  Given the precise nature of 
genetic engineering technology, a scientist might hypothesize that 
genetically engineered food has a higher, or at least similar, likelihood 
of safety compared to food produced from conventional methods.219  
But, in practice, both of these types of food are safe.  And, both types 
of processes—genetic engineering and conventional methods—
should continue to be subject to scientific scrutiny.  Given the many 
decades of research comparing genetically engineered food to 
conventional food, the safety risk of genetically engineered food is the 
same as conventional food.220 
In the rbST example, scientific studies indicate that humans who 
consume milk have elevated levels of IGF-1.221  IGF-1, if unregulated, 
can contribute to the risk of cancer.222  These studies also show that the 
elevated levels of IGF-1 are found regardless of whether the milk is 
from cows treated with rbST or not.223  Therefore, there is no evidence 
suggesting a causal link between milk from rbST treated cows and 
cancer in humans.  Future scientific studies are needed to understand 
why consumption of milk is associated with higher levels of IGF-1 in 
humans.  This scientific uncertainty is different from risk.  In other 
words, no adverse human health events are associated with rbST and, 
the risk of developing cancer from drinking milk from cows treated 
with rbST is similar to drinking milk from cows not treated with rbST.  
The word “cancer” has been associated with strong affect in decision-
making.224  Thus, it is likely that by using the word “cancer” or 
insinuating “cancer” in association with milk treated with rbST in 
advertising, marketing, or internet searches, consumers will 
 
 219  Cf. Conko et al., supra note 78, at 494 (“The essence of these principles is that 
the mere fact that an organism has been modified by recombinant DNA or other 
molecular techniques has no bearing on the degree of hazard or level of risk and 
therefore should not determine whether (or how stringently) the organism is 
regulated.”). 
 220  See supra Section II.B. 
 221  AM. CANCER SOC’Y, supra note 121; see also FDA Report on rBST, supra note 110. 
 222  See Herbert Yu & Thomas Rohan, Role of the Insulin-Like Growth Factor Family in 
Cancer Development and Progression, 92 J. OF THE NAT’L CANCER INST. 1472, 1472 (2000) 
(“Functionally, IGF-1 not only stimulates cell proliferation but also inhibits apoptosis.  
It has now been recognized that the combination of these mitogenic and antiapoptotic 
effects has a profound impact on tumor growth.”).  
 223  AM. CANCER SOC’Y, supra note 121. 
 224  Slovic, The Affect Heuristic, supra note 14, at 1342 (“Thus activities associated with 
cancer are seen as riskier and more in need of regulation than activities associated with 
less dreaded forms of illness, injury, and death (e.g. accidents).”).  
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inappropriately assign risk.  Empirical studies aimed at providing 
consumers with the difference between scientific uncertainty and risk 
may assist consumers with decision-making. 
Some of the controversy surrounding fluoridated water relates to 
using scientific uncertainty to incite fear.  Over many decades, 
scientists continued to research the optimal level of fluoride to add to 
water.  The recommendations have changed over time, with a decrease 
in the optimal amount.225  This does not mean that scientists do not 
understand what they are doing; rather, it means that scientists and 
public health officials are monitoring and adjusting fluoride levels 
based on data.  The risk, however, of not fluoridating water is greater, 
especially in poor populations which have less access to regular dental 
care.  Consumers who oppose fluoridation are weighing risks in the 
wrong direction. 
The debate surrounding embryonic stem cell research raises a 
different concern compared to the other examples.  One postulated 
risk of this type of research could be (or could have been) exploiting 
women for their eggs.226  Strict guidelines for egg donation were 
created.227  Other risks with the application of therapies derived from 
stem cell research are similar to the risks associated with clinical trials 
for any experimental treatment.  In addition, Institutional Review 
Boards have specific guidelines to follow when proposed studies utilize 
embryonic stem cells.228  It would be interesting to study whether 
consumers view clinical trials using treatments derived from embryonic 
stem cell research as riskier than clinical trials using other 
experimental procedures.  And, if consumers perceive greater risk with 
 
 225  Public Health Service Recommendation for Fluoride Concentration in 
Drinking Water for Prevention of Dental Caries, 80 Fed. Reg. 24,936 (May 1, 2015), 
https://www.gpo.gov/fdsys/pkg/FR-2015-05-01/pdf/2015-10201.pdf (“PHS now 
recommends an optimal fluoride concentration of 0.7 milligrams/liter (mg/L).”). 
 226  See Erica Haimes et al., Eggs, Ethics and Exploitation? Investigating Women’s 
Experiences of an Egg Sharing Scheme, 34 SOC. OF HEALTH & ILLNESS 1199, 1199 (2012) 
(“In brief, our analysis suggests that while interviewees acknowledge the potential of 
this scheme to be exploitative, they argue that this is not the case, emphasizing their 
ability to act autonomously in deciding to volunteer.  Nonetheless, these freely made 
decisions do not necessarily take place under circumstances of their choosing.  We 
discuss the implications of this for egg provision in general and for understandings of 
exploitation.”).  
 227  Stem Cell Information, National Institutes of Health Guidelines on Human Stem Cell 
Research, NAT’L INSTS. OF HEALTH, http://stemcells.nih.gov/policy/pages/2009guide 
lines.aspx (last updated Apr. 12, 2015). 
 228  Id.; see, e.g., Form for Egg Donation for Human Embryonic Stem Cell Research (Solely for 
Stem Cell Research), N.Y. DEP’T OF HEALTH, http://stemcell.ny.gov/form-egg-donation-
human-embryonic-stem-cell-research-solely-stem-cell-research (last visited July 4, 
2016). 
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treatments from embryonic stem cell research, then it would be 
valuable to know why that it so.  In this way, information can be 
communicated in order to allow consumers to appropriately assign 
risk. 
In sum, future studies can build on this and incorporate decision-
making research to test how to provide information in a way that allows 
consumers to appropriately assign risk, especially in the scientific arena 
when unknowns exist. 
C.  Theme 3: Explore Different Methods of Communication that 
Consider the Role of Affect and Ambiguity 
Third, the role of affect and ambiguity should be specifically 
considered in studies aimed at effective methods of communication.  
While this is related to Theme 1 (discussed supra Part III.A), the 
emphasis of Theme 3 is to address how to create studies to analyze the 
different marketing forces, especially on the Internet, to understand 
consumer decision-making.  It is certainly not an original idea that 
marketing impacts consumer decision-making or that industry takes 
advantage of this.  It is important, however, to conduct studies not only 
to see how a particular industry or interest group utilizes affect and 
ambiguity to steer consumers away from a particular area of 
biotechnology, but to also test whether different approaches can be 
used to combat a message that creates ambiguity or feelings of 
“badness.”  We know, for example, that consumers are more likely to 
appropriately assign risk if they understand the science.  We also know 
that consumers are less likely to appropriately assign risk when they 
receive ambiguous information.  The question becomes how to 
communicate the information in a way that recognizes the role of 
affect and ambiguity. 
Various approaches appear to be underway.  An entire website 
highlights stories about how VHPs changed their position once one of 
their children contracted a vaccine-preventable disease.229  Recent 
commentary in this area suggests that VHPs have little ability to weigh 
the risks because of a lack of personal experience with the 
consequences and complications associated with these diseases.230  
Thus, the vaccine-preventable diseases, such as polio, measles and 
 
 229  Tara Hills, We Learned the Hard Way, VOICES FOR VACCINES (May 24, 2016), 
http://www.voicesforvaccines.org/we-learned-the-hard-way/. 
 230  See, e.g., Emmi S. Herman, Measles and My Sister, VOICES FOR VACCINES (May 24, 
2016), http://www.voicesforvaccines.org/measles-and-my-sister/ (“[T]oday’s parents 
and physicians are less likely to have had any personal experience with the cruel 
disease.”). 
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mumps, may not seem real or deadly.231  But, once a parent sees his/
her child with the disease, the parent might feel differently about the 
risk of vaccines.  Using VHPs who changed their position might seem, 
intuitively, as a good way to assist parents in assigning risks to 
vaccinations.232  A former-VHP might be in a good position to reach a 
current-VHP in a way that is different than how they might respond to 
a pharmaceutical company.  This type of approach should be 
empirically tested to see if it has the desired response.  Is it, for 
example, impacting how VHPs make decisions?  In other words, do 
consumers respond differently to different sources that they perceive 
as credible?  Studies aimed at understanding how consumers respond 
to different sources (and marketing related thereto) may provide 
insight as how to allow consumers to appropriately assign risk.  It is 
important to compare how consumers respond to anti-vaccine 
marketing techniques versus experimental pro-vaccine marketing 
techniques.  Understanding which techniques and why they are 
effective (or ineffective) is important to communicate with consumers 
(and marketing experts have known this for decades), but this theme 
aims to suggest studies that utilize affect and ambiguity theories to 
reach consumers in a way that gives them the ability to appropriately 
assign risk. 
Similarly, with GMOs, the question is: what is the most effective 
method of communication regarding the application of the 
technology?  Studies aimed at comparing different messengers of the 
technology—big corporations, publicly funded agriculture scientists, 
small farmers, organic farmers (who may not oppose genetic 
engineering technology), mothers, children, or others—could assist 
with understanding how these communication methods allow 
consumers to more appropriately assign risk.  The experimental 
conditions should be compared to the current marketing techniques 
that consumers already experience.  Studies aimed at digesting the role 
of affect and ambiguity, especially if the credibility of sources is at issue, 
will be important for communication tactics. 
The controversy surrounding rbST has many similarities to 
GMOs.  Studies aimed at developing communication tactics that 
consider affect and ambiguity as part of the decision-making process 
need to be conducted.  If consumers are concerned about animal 
welfare, then perhaps veterinarians might be a potential messenger to 
 
 231  Cf. id. 
 232  For examples and stories of VHPs who changed their positions, see Anti-Vax to 
Pro-Vax, VOICES FOR VACCINES (May 24, 2016), http://www.voicesforvaccines.org/ 
category/anti-vax-to-pro-vax/.  
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provide accurate information regarding animal welfare.  If consumers 
are concerned about adverse human health consequences, scientists 
and physicians might be good messengers.  In these groups of 
messengers, it would be interesting to compare variables, such as 
whether the veterinarians, scientists and physicians are from 
universities versus the private sector, or whether they receive their 
financial support from the private sector or government grants.  By 
using techniques that allow for testing affect and ambiguity with these 
different variables (including software aimed at behavioral research 
studies), it may be possible for policymakers to provide accurate 
information from trusted sources. 
Fluoridated water programs suffer from the same issues described 
above.  Since most consumers are exposed to the public water supply 
through homes, schools, restaurants, etc., it is important that 
consumers make informed decisions about this public program.  Fear 
of adverse events associated with fluoridated water impacts decision-
making.  Studies aimed at examining how to provide accurate 
information to consumers about fluoride are needed.  An example of 
a specific study might be to compare how consumers respond to a 
widespread campaign of posting factual information using signs about 
fluoridated water supplies in various public places, including post 
offices, restaurants, hospitals, and grocery stores.  Three sets of signs 
can be designed: one set that suggests feelings of “goodness,” another 
set that suggests feelings of “badness,” and a final set that does not 
suggest a particular feeling.  A fourth group would not see any signs.  
Follow-up survey questions can compare consumer responses to 
fluoridated water programs.  If groups respond differently, this would 
suggest that providing (or marketing) accurate information in a way 
that incorporates affect impacts consumer decision-making. 
Despite contemporary advances in medicine, we still currently 
have many untreatable and highly debilitating diseases, such as 
Alzheimer’s disease.  Scientists hope that embryonic stem cell research 
may open doors to create cures for currently un-curable diseases.233  
Patients and family members are searching for treatments and cures 
for highly debilitating diseases—often with the patient participating in 
 
 233  See, e.g., Stem Cell Basics – What are the potential uses of human stem cells and the 
obstacles that must be overcome before these potential uses will be realized?, NAT’L INSTS. OF 
HEALTH, http://stemcells.nih.gov/info/basics/pages/basics6.aspx (last updated Mar. 
5, 2015) (“In people who suffer from type 1 diabetes, the cells of the pancreas that 
normally produce insulin are destroyed by the patient’s own immune system.  New 
studies indicate that it may be possible to direct the differentiation of human 
embryonic stem cells in cell culture to form insulin-producing cells that eventually 
could be used in transplantation therapy for persons with diabetes.”). 
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early clinical trials.234  It would be interesting to compare 
communications from patients (and their family members), 
physicians, and scientists to understand if consumers respond 
differently.  It may also be possible to separate out those that oppose 
embryonic stem cell research for purely moral reasons versus those 
that oppose embryonic stem cell research based on reasons related to 
affect or ambiguity.  Focus groups, similar to the study design used by 
Blaisdell and colleagues, may provide helpful information to identify 
underlying rationales. 
The debates surrounding controversial biotechnology discussed 
in this article suffer from communication and marketing issues.  
Consumers are provided with conflicting information, often with 
emotional undertones, which impacts their ability to assign risk to the 
application of the underlying technology.235  Given consumer mistrust 
of pharmaceutical companies, other tactics are needed to 
communicate the risks and benefits to consumers.236  Is it possible for 
big agricultural and pharmaceutical companies to build (or re-build) 
the reputational value that other big companies, such as Costco, 
appear to have with consumers?237  Would brand-enhancement in these 
industries even have an impact?  Studies can be conducted to compare 
consumer perceptions of risk based on brand reputation.  Or, perhaps, 
are personal stories (by former VHPs, for example) more effective in 
allowing consumers to assign risk?  Or, are there particular celebrities 
or other well-known people who could be influential by saying that 
they, inter alia, vaccinate their children, or eat food from GMOs?  
Future studies can assess the role of affect and ambiguity by comparing 
various communications and marketing approaches. 
 
 234  See NIH Clinical Research Trials and You, The Basics, NAT’L INSTS. OF HEALTH, 
https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics (last 
updated Apr. 29, 2016) (“Participants with an illness or disease also participate to help 
others, but also to possibly receive the newest treatment and to have the additional 
care and attention from the clinical trial staff.  Clinical trials offer hope for many 
people and an opportunity to help researchers find better treatments for others in the 
future.”).  
 235  Cf. Johnson, supra note 184 (“A study published this month on the Proceedings 
of the National Academy of Sciences suggested that it is more effective to appeal to 
anti-vaxxers through their emotions, with stories and pictures of children sick with 
measles, the mumps or rubella––a reminder that subjective feelings are still trusted 
over scientific expertise.”). 
 236  See, e.g., Kessel, supra note 164, at 988–90. 
 237  Bryan Pearson, In Brand We Trust: How Recalls at Trader Joe’s, Costco, Can Enhance 
Customer Engagement, FORBES (May 18, 2016, 4:33 PM), http://www.forbes.com/sites/ 
bryanpearson/2016/05/18/in-brand-we-trust-how-recalls-at-trader-joes-costco-can-
enhance-customer-engagement/#4661c92e77f4 (“Research shows there is an appetite 
for brand reliability, even if it reveals fallibility.”).  
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D.  Theme 4: Address the Difference between Values, Affect and 
Ambiguity in Decision-Making 
This theme presents a particular challenge.  How should 
policymakers address conflicting information and differentiate 
between value-based decisions and decisions impacted by affect and 
ambiguity?  The theory of evolution provides a nice example of this 
dilemma.  Evolution, for example, is probably the most accepted 
scientific theory ever, yet the public perception is that scientists do not 
have a consensus.238  A recent Pew Research survey showed: 
While 98% of scientists connected to the American 
Association for the Advancement of Science say they believe 
humans evolved over time, only two-thirds (66%) of 
Americans overall perceive that scientists generally agree 
about evolution, according to 2014 data from a recent Pew 
Research Center survey on science and society.  Those in the 
general public who reject evolution are divided on whether 
there is a scientific consensus on the topic, with 47% saying 
scientists agree on evolution and 46% saying they do not.239 
Are consumers receiving conflicting information that leads them to 
believe that scientists do not agree?  If so, it is important to understand 
where these consumers are receiving their information.  Perhaps 
consumers are receiving information from religious sources that 
disagree with the scientific consensus.240  It becomes very difficult to 
address how to tackle the presentation of conflicting information from 
trusted sources, especially if individual values are at play.  This is a 
particular challenge for policymakers.  Studies aimed at effectively 
separating the role of affect and ambiguity from value-driven decisions 
will be important for implementing evidence-based policies. 
In the vaccination controversy, it is important to separate whether 
VHPs are making value-based decisions or risk-based decisions.  VHPs 
may feel strongly about their position; that is, for them, it feels like a 
value based decision.  Or, the role of autonomy, certainly a legal value, 
may be implicated in a VHP’s decision.  Studies are needed to dissect 
the difference between a value-based decision and a risk perception 
decision.  The value of autonomy presents major challenges in 
 
 238  See, e.g., David Masci, On Darwin Day, 5 Facts About the Evolution Debate, PEW RES. 
CTR. (Feb. 12, 2016), http://www.pewresearch.org/fact-tank/2016/02/12/darwin-
day/. 
 239  Id. 
 240  Id. (“Of all the major religious groups in the U.S., evangelical Protestants are 
among the most likely to reject evolution.  According to the Religious Landscape 
Study, a solid majority (57%) of evangelicals say humans and other living things have 
always existed in their present form.”).  
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implementing major public health policies.  It is possible, however, to 
try to understand whether VHPs believe they are making a value-based 
versus risk-based decision.  If it is possible to provide information in a 
way that allows VHPs to appropriately assign risk to a decision to 
vaccinate, then it is fair to characterize it as a risk-perception decision.  
Accurate information can be provided to subjects regarding the risks 
of vaccinating and non-vaccinating and then follow-on questions can 
be presented to subjects that are framed as testing values versus risk 
and comparing the answers. 
While some of the resistance to GMOs may be due to an 
inappropriate assignment of risk, another possibility is a moral/value-
based opposition to changing the DNA.  Put differently, a value-based 
opposition may be that science is interfering with “God’s design.”241  
This is a particularly interesting value-based opposition because 
conventional breeding also mutates DNA, albeit with less precision.  
Once again, it is important to learn whether consumers are making 
decisions based on values or perceptions of risk.  Studies addressing 
consumer concerns about health, safety and environment of food 
produced from GMOs compared to understanding value-based 
decisions will be important to understand the reasons underlying 
consumer decision-making. 
The controversy surrounding rbST does not appear to have the 
same ethical or value-driven concerns as seen in other examples 
discussed within this article.  However, treatment of cows with rbST 
certainly could raise these same types of issues because the rbST allows 
cows to continue to produce milk in an artificial setting.  Despite that 
the public controversy around rbST is not cast in a value-driven 
dialogue, it would still be interesting to test whether values are at play 
in consumer decision-making.  And, perhaps, a more interesting 
question is to understand why this type of biotechnology has not 
suffered from the same values-driven debate as vaccines, GMOs, and 
embryonic stem cell research.  Studies aimed at separating why some 
forms of biotechnology are heavily value-laden or not may provide 
powerful insight to address the more controversial examples provided 
herein. 
The controversy surrounding fluoridated water implicates the 
 
 241  Jonathan Frochtzwajg, Playing God? Many Faiths Agree that Tinkering with Genes is 
Out of Bounds, THE GENETIC LITERACY PROJECT (May 7, 2015), 
https://www.geneticliteracyproject.org/2015/05/07/playing-god-many-faiths-agree-
that-tinkering-with-genes-is-out-of-bounds/ (“Religious views on GMOs are as varied as 
religious traditions themselves, but there are some common theological threads.  Chief 
among them: the belief that to change genetic material is to play God.”). 
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value of autonomy.  Since it is very hard to opt out of exposure to the 
public water supply, fluoridation programs violate individual 
autonomy.  The value of autonomy is not unlimited.  As drivers on the 
road, we cannot drive wherever we want; instead, we are required to 
obey traffic rules.  Rules that are meant to benefit the public often 
violate individual autonomy.  For fluoridated water programs, 
scientific data demonstrates that the benefit to the public greatly 
exceeds any risk.  Studies aimed at communicating fluoridated water 
programs as similar to other public benefit programs may assist to 
override an objection based on autonomy. 
The debate about embryonic stem cell research highlights the 
issues that arise with addressing the difference between decisions 
based on values versus decisions that implicate affect and ambiguity.  
In a previous study analyzing information provided to consumers 
about federal funding of embryonic stem cell research, articles 
(including editorials) in mainstream newspapers that suggested adult 
stem cells could provide that same information as embryonic stem cells 
was not supported by the scientific evidence at the time.242  Consumers 
were asked to weigh-in on the funding of embryonic stem cell research, 
but they were provided with contradictory information—that is, that 
adult stem cells could provide similar information as embryonic stem 
cells, thus avoiding the need to fund a controversial area of research.  
Values and emotions related thereto were also incorporated in the 
discussion.  This is not to say that consumers cannot be opposed to 
embryonic stem cell research; rather, a difference exists between a 
value-based decision and a decision based on ambiguous information.  
Put differently, a moral opposition is different than a decision based 
on ambiguity. 
E.  The Role of Risk-Perception in Policymaking 
Empirically testing ways to provide accurate information in a way 
that considers consumer decision-making has some complications and 
limitations.  Accurately providing scientific information necessarily 
means that there is always some degree of uncertainty.  Opponents to 
controversial biotechnology exploit scientific uncertainty.  Simply 
telling consumers that the unknown risks are likely small will not 
assuage consumers and will not allow them to appropriately assign risk.  
While factsheets by the Center for Disease Control, Food and Drug 
Administration and National Institutes of Health are important, they 
do not necessarily reach the weary and overwhelmed consumer.  Since 
 
 242  Sax, The Separation of Politics and Science, supra note 146, at 7–14. 
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consumers are wading through both information and misinformation, 
various tactics have to be employed to allow consumers to make 
informed choices.  These tactics should utilize decision-making 
research to provide information in a way that allows the consumer to 
appropriately assign risk. 
The above discussion should not be conflated with the issue that 
scientific exploration should be ongoing.  Some uncertainty exists 
within well-accepted scientific theories—which necessitate additional 
and ongoing research.  But, this should not be confused with how 
consumers assign risk.  For example, an overwhelming amount of data 
demonstrates that vaccines prevent death and disability from a variety 
of diseases.  This does not mean that research on safety and efficacy of 
vaccines should end.  The scientific community should continue to 
research, revise, question, and improve vaccines.  But, it does mean 
that we have enough evidence to implement widespread vaccination 
policies.  Thus, while scientific research will continue on vaccines, 
consumers should appropriately assign a low risk (and high benefit) to 
standard vaccinations. 
In line with ongoing scientific exploration, the policies 
surrounding the applications of biotechnology should be analyzed and 
revisited on an ongoing basis.  Since scientific uncertainty exists, 
additional studies will almost always be warranted.  Government 
officials, public health experts, physicians, and scientists must 
collaborate to analyze issues from the basic sciences to change policies 
on an on-going basis.  Widespread implementation of policies—
especially as it relates to biotechnology—needs to be accomplished 
with living documents.  Risks must be minimized, but will likely never 
be eliminated.  Put differently, a small risk from a vaccine is still a much 
smaller risk than not being vaccinated and developing a potentially 
deadly disease.  It is the risk/benefit ratio that needs to govern policies, 
not whether any risk could exist at any time.  Communicating 
information in a manner that allows consumers to appropriately assign 
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CONCLUSION 
We have major societal challenges and problems to solve.  This 
article bridges together scientific studies, policy implementation, and 
decision-making research particularly as to the role of affect and 
ambiguity in consumer perceptions of risk.  Understanding consumer 
concerns is important to implementing wide-ranging policies, 
especially in controversial areas such as biotechnology.  Given that 
some degree of scientific uncertainly always exists, it is important for 
policy makers to communicate information in a way that allows 
consumers to appropriately assign risk.  By combining research from a 
variety of disciplines, this article articulates common themes that run 
through each area of consumer concerns.  The thematic approach 
provides general considerations for policy implementation.  Within 
each theme, specific studies are needed that are based on the data and 
information that we already have about consumer resistance to certain 
policies.  By giving general suggestions of future studies, this article 
highlights the distinct issues that face each specific area of technology, 
particularly with respect to consumer concerns and decision-making.  
This article compares how different studies may assist in 
understanding how to address consumer decision-making and 
provides a roadmap for future directions in this area. 
 
